UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014.
or

¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________.
Commission File Number: 001-35735
Assured Pharmacy, Inc.
(Exact name of registrant as specified in its charter)

Nevada | 98-0233878
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

5600 Tennyson Parkway, Suite 390, Plano, TX 75024
(Address of principal executive offices) (Zip Code)
(972) 473-4033
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of Exchange Act.

Large accelerated filer ¨ | Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company) | Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class |  | Outstanding at August 11, 2014
Common Stock, $0.001 par value |  | 11,303,294

Table of Contents
Form 10-Q
Assured Pharmacy, Inc.
June 30, 2014
Table of Contents

|  |  | Page(s)
Part I. | FINANCIAL INFORMATION |  | 3
Item 1. | Financial Statements |  | 3 - 26
| Condensed Consolidated Balance Sheets – June 30, 2014 (Unaudited) and December 31, 2013 |  | 3
| Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2014 and 2013 (Unaudited) |  | 4
| Condensed Consolidated Statement of Stockholders’ Deficit for the Six Months Ended June 30, 2014 and 2013 (Unaudited) |  | 5
| Condensed Consolidated Statements of Cash Flow for the Six Months Ended June 30, 2014 (Unaudited) |  | 6
| Notes to the Condensed Consolidated Financial Statements (Unaudited) |  | 7
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 27 - 38
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |  | 38
Item 4. | Controls and Procedures |  | 38
Part II. | OTHER INFORMATION |  | 39
Item 1. | Legal Proceedings |  | 39
Item 1A. | Risk Factors |  | 39
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |  | 40
Item 3. | Defaults upon Senior Securities |  | 40
Item 4. | Mine Safety Disclosures |  | 40
Item 5. | Other Information |  | 40
Item 6. | Exhibits |  | 40
SIGNATURES |  |  | 41
EXHIBITS |  |  | 42
CERTIFICATIONS |  |  | 42

- 2 -

Table of Contents
Part I – Financial Information
Item 1 - Financial Statements.
ASSURED PHARMACY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

|  | June 30, |  |  | December 31, |
|  | 2014 |  |  | 2013 |
|  | (Unaudited) |  |  |  |
ASSETS |  |  |  |  |  |
Current Assets |  |  |  |  |  |
Cash |  | $ | 24,779 |  |  | $ | 2,856 |
Accounts receivable, net |  |  | 29,898 |  |  |  | 323,965 |
Inventories |  |  | 273,155 |  |  |  | 273,195 |
Prepaid and other current assets |  |  | 205,684 |  |  |  | 226,217 |
Assets of discontinued operations, net |  |  | 468 |  |  |  | 4,048 |
Total current assets |  |  | 533,984 |  |  |  | 830,281 |
Property and equipment, net |  |  | 75,915 |  |  |  | 78,094 |
Assets of discontinued operations, net |  |  | 136,440 |  |  |  | 140,563 |
TOTAL ASSETS |  | $ | 746,339 |  |  | $ | 1,048,938 |
LIABILITIES AND STOCKHOLDERS' DEFICIT |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  | $ | 1,808,244 |  |  | $ | 1,642,518 |
Liabilities of discontinued operations |  |  | 95,649 |  |  |  | 150,652 |
Unsecured convertible debentures, net of discount |  |  | 396,664 |  |  |  | 357,528 |
Notes payable to related parties |  |  | 240,000 |  |  |  | - |
Notes payable |  |  | 3,867,330 |  |  |  | 3,830,637 |
Total current liabilities |  |  | 6,407,887 |  |  |  | 5,981,335 |
Notes payable, net of current portion |  |  | 8,849 |  |  |  | 25,882 |
Notes payable to related parties, net of current portion |  |  | 727,000 |  |  |  | 477,000 |
Unsecured convertible debentures, net of current portion and discount |  |  | 1,102,290 |  |  |  | 1,142,472 |
Unsecured convertible debentures-related party, net of current portion and discount |  |  | - |  |  |  | - |
Derivative liability |  |  | 185,397 |  |  |  | 312,088 |
Warrant liability |  |  | 759,749 |  |  |  | 1,060,353 |
TOTAL LIABILITIES |  |  | 9,191,172 |  |  |  | 8,999,130 |
Commitments and Contingencies (see Note 8) |  |  |  |  |  |  |  |
Series D redeemable convertible preferred stock; par value $0.001 per share; 15,000 |  |  | 3,177,526 |  |  |  | 2,515,469 |
shares authorized, 1,926 and 1,070 issued and outstanding, respectively |  |  |  |  |  |  |  |
Assured Pharmacy, Inc.'s Stockholders' Deficit |  |  |  |  |  |  |  |
Preferred stock; par value $0.001 per share; 5,000,000 shares authorized, 2,830 |  |  |  |  |  |  |  |
shares designated to Series A convertible, 7,745 shares designated to Series B |  |  |  |  |  |  |  |
convertible, 813 shares designated to Series C convertible |  |  |  |  |  |  |  |
Series A convertible preferred stock; par value $0.001 per share; 2,830 |  |  |  |  |  |  |  |
shares authorized, 1,466 and 1,466 issued and outstanding, respectively |  |  | 1 |  |  |  | 1 |
Series C convertible preferred stock; par value $0.001 per share; 813 |  |  |  |  |  |  |  |
shares authorized, 813 and 813 issued and and outstanding, respectively |  |  | 1 |  |  |  | 1 |
Series B convertible preferred stock; par value $0.001 per share; 7,745 |  |  |  |  |  |  |  |
shares authorized, 5,124 and 5,124 issued and outstanding, respectively |  |  | 5 |  |  |  | 5 |
Common stock; par value $0.001 per share; 35,000,000 shares authorized, |  |  |  |  |  |  |  |
11,503,294 and 10,255,693 issued and outstanding, respectively |  |  | 11,503 |  |  |  | 10,256 |
Additional paid-in capital, net |  |  | 38,319,672 |  |  |  | 38,142,048 |
Accumulated deficit |  |  | (49,953,541 | ) |  |  | (48,617,972 | )
Stockholders' deficit |  |  | (11,622,359 | ) |  |  | (10,465,661 | )
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT |  | $ | 746,339 |  |  | $ | 1,048,938 |

See accompanying notes to these condensed consolidated financial statements.
- 3 -

Table of Contents
ASSURED PHARMACY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013
(UNAUDITED)

|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013 |
Sales |  | $ | 2,177,197 |  |  | $ | 1,380,955 |  |  | $ | 3,797,389 |  |  | $ | 3,073,500 |
Cost of sales |  |  | 1,765,861 |  |  |  | 1,060,425 |  |  |  | 3,049,675 |  |  |  | 2,378,348 |
Gross profit |  |  | 411,336 |  |  |  | 320,530 |  |  |  | 747,714 |  |  |  | 695,152 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salaries and related expenses |  |  | 499,487 |  |  |  | 520,642 |  |  |  | 939,767 |  |  |  | 1,034,331 |
Selling, general and administrative |  |  | 466,586 |  |  |  | 788,314 |  |  |  | 913,205 |  |  |  | 1,319,704 |
Total operating expenses |  |  | 966,073 |  |  |  | 1,308,956 |  |  |  | 1,852,972 |  |  |  | 2,354,035 |
Loss from continuing operations |  |  | (554,737 | ) |  |  | (988,426 | ) |  |  | (1,105,258 | ) |  |  | (1,658,883 | )
Other expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | 163,233 |  |  |  | 302,631 |  |  |  | 322,449 |  |  |  | 582,017 |
Gain on extinguishment of debt |  |  | - |  |  |  | - |  |  |  | (213,433 | ) |  |  | - |
Gain on change in fair value of forward contract liability |  |  | - |  |  |  | 35,418 |  |  |  | - |  |  |  | 97,632 |
Gain on change in fair value of derivative |  |  | (64,650 | ) |  |  | - |  |  |  | (126,691 | ) |  |  | - |
Gain on change in fair value of warrant liability |  |  | (119,711 | ) |  |  | (247,295 | ) |  |  | (444,016 | ) |  |  | (138,331 | )
Total other (income) expense |  |  | (21,128 | ) |  |  | 90,754 |  |  |  | (461,691 | ) |  |  | 541,318 |
Loss from continuing operations before income tax |  |  | (533,609 | ) |  |  | (1,079,180 | ) |  |  | (643,567 | ) |  |  | (2,200,201 | )
Income tax expense |  |  | 5,126 |  |  |  | 268,920 |  |  |  | 10,481 |  |  |  | 273,117 |
Loss from continuing operations, net of tax |  |  | (538,735 | ) |  |  | (1,348,100 | ) |  |  | (654,048 | ) |  |  | (2,473,318 | )
Discontinued operations: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss from operations of discontinued pharmacies, net of tax benefit |  |  | (9,519 | ) |  |  | (499,422 | ) |  |  | (19,464 | ) |  |  | (507,217 | )
Net loss |  | $ | (548,254 | ) |  | $ | (1,847,522 | ) |  | $ | (673,512 | ) |  | $ | (2,980,535 | )
Milestone adjustment on preferred stock |  |  | - |  |  |  | - |  |  |  | (662,057 | ) |  |  | - |
Net loss applicable to common stock |  | $ | (548,254 | ) |  | $ | (1,847,522 | ) |  | $ | (1,335,569 | ) |  | $ | (2,980,535 | )
Basic and diluted loss per common share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss to common stockholders from continuing operations |  | $ | (0.05 | ) |  | $ | (0.23 | ) |  | $ | (0.12 | ) |  | $ | (0.46 | )
Loss from discontinued operations, net of tax expense (benefit) |  | $ | - |  |  | $ | (0.09 | ) |  | $ | - |  |  | $ | (0.09 | )
Net loss per common share - basic and diluted |  | $ | (0.05 | ) |  | $ | (0.32 | ) |  | $ | (0.12 | ) |  | $ | (0.56 | )
Basic and diluted weighted average number of common shares outstanding |  |  | 11,503,294 |  |  |  | 5,817,053 |  |  |  | 11,414,481 |  |  |  | 5,361,577 |

See accompanying notes to these condensed consolidated financial statements.
- 4 -

Table of Contents
ASSURED PHARMACY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2014
(Unaudited)

|  | ASSURED PHARMACY, Inc. Stockholders |  |  |  |
|  |  |  |  |  |  |  | Series A |  |  | Series C |  |  | Series B |  |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Preferred Stock |  |  | Preferred Stock |  |  | Preferred Stock |  |  | Additional |  |  |  |  |  | Total |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Paid In |  |  | Accumulated |  |  | Stockholders' |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Deficit |
Balance December 31, 2013 |  |  | 10,255,693 |  |  | $ | 10,256 |  |  |  | 1,466 |  |  | $ | 1 |  |  |  | 813 |  |  | $ | 1 |  |  |  | 5,124 |  |  | $ | 5 |  |  | $ | 38,142,048 |  |  | $ | (48,617,972 | ) |  | $ | (10,465,661 | )
Issuance of common stock in lieu of interest on refinancing |  |  | 420,694 |  |  |  | 420 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 62,684 |  |  |  |  |  |  |  | 63,104 |
Issue of common stock for make-whole adjustment on private placement |  |  | 826,907 |  |  |  | 827 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 114,940 |  |  |  |  |  |  |  | 115,767 |
Milestone adjustement for preferred stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (662,057 | ) |  |  | (662,057 | )
Net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (673,512 | ) |  |  | (673,512 | )
Balance June 30, 2014 |  |  | 11,503,294 |  |  | $ | 11,503 |  |  |  | 1,466 |  |  | $ | 1 |  |  |  | 813 |  |  | $ | 1 |  |  |  | 5,124 |  |  | $ | 5 |  |  | $ | 38,319,672 |  |  | $ | (49,953,541 | ) |  | $ | (11,622,359 | )

See accompanying notes to these condensed consolidated financial statements.
- 5 -

Table of Contents
ASSURED PHARMACY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013
(Unaudited)

|  | Six months ended June 30, |
|  | 2014 |  |  | 2013 |
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |
Net loss applicable to common stock |  | $ | (673,512 | ) |  | $ | (2,980,535 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |
Depreciation and amortization of property and equipment |  |  | 13,915 |  |  |  | 15,620 |
Amortization of debt issuance costs |  |  | 2,737 |  |  |  | 19,534 |
Amortization of discount on debt |  |  | 27,603 |  |  |  | 175,745 |
Stock based compensation |  |  | 99,937 |  |  |  | 426,778 |
Issuance of comm on stock in lieu of debenture interest |  |  | - |  |  |  | 45,467 |
Gain on extinguishment of debentures |  |  | (213,433 | ) |  |  | - |
Provision for accounts receivable doubtful accounts |  |  | 15,540 |  |  |  | 4,404 |
Recoveries of other receivables doubtful accounts |  |  | (7,757 | ) |  |  | (40,097 | )
Loss on change in fair value of forward contract |  |  | - |  |  |  | 97,632 |
Impairment of goodwill |  |  | - |  |  |  | 697,766 |
Gain on change in fair value of derivative |  |  | (126,691 | ) |  |  | - |
Gain on change in fair value of warrant liability |  |  | (444,016 | ) |  |  | (138,331 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 282,106 |  |  |  | 264,263 |
Inventories |  |  | 40 |  |  |  | 137,888 |
Prepaid expenses and other current assets |  |  | 67,859 |  |  |  | (25,882 | )
Other receivables |  |  | 11,880 |  |  |  | 63,039 |
Accounts payable and accrued liabilities |  |  | 478,907 |  |  |  | 400,511 |
Net cash used in operating activities |  |  | (464,885 | ) |  |  | (836,198 | )
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (11,736 | ) |  |  | (47,649 | )
Net cash used in investing activities |  |  | (11,736 | ) |  |  | (47,649 | )
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |
Repayment of notes payable |  |  | (10,340 | ) |  |  | (43,320 | )
Proceeds from issuance of common stock |  |  | - |  |  |  | 860,000 |
Payment of issuance costs for common stock |  |  | - |  |  |  | (45,810 | )
Proceeds from issuance of Series A preferred stock |  |  | - |  |  |  | 60,000 |
Proceeds from notes payable, related party |  |  | 440,000 |  |  |  | - |
Proceeds from advances on revolving note |  |  | 80,000 |  |  |  | - |
Repayment of advances on revolving note |  |  | (50,000 | ) |  |  | - |
Repayment of convertible debentures |  |  | (11,116 | ) |  |  | - |
Proceeds from advances on shareholder revolving note |  |  | 50,000 |  |  |  | 270,500 |
Repayment of advances on shareholder revolving note |  |  | - |  |  |  | (229,500 | )
Net cash provided by financing activities |  |  | 498,544 |  |  |  | 871,870 |
Net decrease in cash |  |  | 21,923 |  |  |  | (11,977 | )
Cash at beginning of period |  |  | 2,856 |  |  |  | 21,298 |
Cash at end of period |  | $ | 24,779 |  |  | $ | 9,321 |

See accompanying notes to these condensed consolidated financial statements.
- 6 -

Table of Contents
ASSURED PHARMACY, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. BASIS OF PRESENTATION AND PLAN OF OPERATIONS
The unaudited condensed interim consolidated financial statements as of and for the three and six months ended June 30, 2014 and 2013 have been prepared by Assured Pharmacy, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. These consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary for a fair statement for the periods presented. The year-end consolidated data was derived from audited financial statements but does not include all disclosures required by GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the full fiscal year.
These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company and notes thereto included in the audited annual financial statements for the year ended December 31, 2013 filed as part of the Company’s Annual Report on Form 10-K/A on April 25, 2014.
Going Concern Considerations
The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. As of June 30, 2014, the Company had an accumulated deficit of approximately $50.0 million and, recurring losses from operations. The Company also had negative working capital of approximately $5.9 million and debt with maturities within one year in the amount of approximately $4.5 million as of June 30, 2014.
The Company intends to fund operations through raising additional capital through debt financing and equity issuances, increased sales, increased collection activity on past due other receivable balances and reduced expenses, which may be insufficient to fund its capital expenditures, working capital or other cash requirements for the year ending December 31, 2014. The Company is in negotiations with current debt holders to restructure and extend payment terms of the existing short term debt. The Company is seeking additional funds to finance its immediate and long-term operations. The successful outcome of future financing activities cannot be determined at this time and there is no assurance that if achieved, the Company will have sufficient funds to execute its intended business plan or generate positive operating results. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.
In response to these financial issues, management has taken the following actions:
● The Company is seeking to renegotiate existing debt.
● The Company is seeking investment capital.
● The Company is aggressively targeting new physicians.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States (“U.S. GAAP”) in all material respects, and have been consistently applied in preparing the accompanying consolidated financial statements.
- 7 -

Table of Contents
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Significant estimates and assumptions involved include the collectability of accounts receivable, accounting for stock-based compensation and other stock-based payments, convertible debt issuances, the valuation of the deferred tax asset, inventory, warrant liability and long-lived assets valuation. Actual results could materially differ from these estimates.
Risks and Uncertainties
The Company operates in a highly competitive industry that is subject to intense competition. The Company faces risks and uncertainties relating to its ability to successfully implement its business strategy. Among other things, these risks include the ability to develop and sustain revenue growth; managing and expanding operations; competition; attracting, retaining and motivating qualified personnel; maintaining and developing new strategic relationships; and the ability to anticipate and adapt to the changing markets and any changes in government regulations.
As a result, the Company may be subject to the risk of delays in obtaining (or failing to obtain) regulatory clearance and other uncertainties, including financial, operational, technological, regulatory and other risks associated with an emerging business, including the risk of business failure.
The Company’s pharmacies are subject to licensing and regulation by the health, sanitation, safety, building and fire agencies in the state or municipality where located. Difficulties or failures in obtaining or maintaining the required licensing and/or approvals could prevent the continued operations of such pharmacies. Management believes that the Company is operating in compliance with all applicable laws and regulations.
Revenue Recognition
The Company recognizes revenue from prescriptions dispensed on an accrual basis when the product is delivered to or picked up by the customer. Payments are received directly from the customer at the point of sale, or the customers’ insurance provider is billed electronically. For third party medical insurance and other claims, authorization to ensure payment is obtained from the customer’s insurance provider before the medication is dispensed to the customer. Authorization is obtained for these sales electronically and a corresponding authorization number is issued by the customers’ insurance provider.
Discontinued Operations
Discontinued operations include our Gresham and Riverside pharmacies that were closed in August 2013 due to our Company’s financial condition. Management considered several factors in determining which two pharmacies to close, including historical financial performance, regulatory costs, current sales prospects, geographic and physical location and strength of existing physician relationships. After consideration of these factors, management closed our Gresham and Riverside pharmacies. These closures met the discontinued operations criteria and, accordingly, are included in discontinued operations for all periods presented.
Accounts Receivable and Allowances
The Company’s accounts receivable consist of amounts due from third party medical insurance carriers, pharmacy benefit management companies, patients and credit card processors. Management periodically reviews the accounts receivable to assess collectability and estimate potential doubtful accounts. Accounts receivable are written-off after collection efforts have been completed in accordance with the Company’s policies. The doubtful accounts allowance reduces the carrying value of the account receivable.
In March 2014, the Company entered into a $600,000 Non-Disclosable Revolving Line of Credit Loan with Third Coast Bank SSB due on March 25, 2015. The loan is not subject to an interest rate, but is subject to service charges based on the amount of funds advanced. The credit facility allows for the sale of receivables at collectible value less a 10% reserve to be maintained based on the outstanding balance of receivables sold. The loan is secured by the Company’s accounts receivable and is guaranteed by Pinewood Trading Fund, LP, a related party. The Company recorded the sale of the accounts receivable by reducing the accounts receivable for the accounts receivable sold with recourse, net of the 10% reserve required.
In June 2014, the Company entered into a modification of the $600,000 Non-Disclosable Revolving Line of Credit due March 25, 2015 whereby the Revolving Line of Credit was increased to $1,200,000 and the maturity date was extended to June 5, 2015.
- 8 -

Table of Contents
The Company’s accounts receivables are detailed as follows:

|  | June 30, 2014 |  |  | December 31, 2013 |
Accounts receivable |  |  |  |  |  |
Third party medical insurance and other |  | $ | 598,903 |  |  | $ | 324,095 |
Allowance for doubtful accounts |  |  | (7,771 | ) |  |  | (130 | )
Accounts receivable sold with recourse, net of reserve |  |  | (561,234) |  |  |  | - |
Total accounts receivable, net |  | $ | 29,898 |  |  | $ | 323,965 |

The provision for bad debts for the six months ended June 30, 2014 and 2013 was $18,912 and $9,564, respectively.
Stock-based Compensation
The Company issues options and restricted shares of common stock to employees and consultants. Stock option and restricted share awards are granted at the fair market value of the Company’s common stock on the date of grant.
The Company records all share-based payments at fair value. The total applicable compensation cost is amortized on a straight-line basis over the requisite service period, which is generally the vesting period.
For the six months ended June 30, 2014 and 2013, the Company recognized $99,937 and $426,778, respectively, in compensation expense which is included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations.
Reclassification
Certain prior year amounts have been reclassified to conform to the 2014 financial statement presentation. The reclassifications did not affect net loss attributable to the Company, cash flows, assets, liabilities or equity for the periods presented.
Basic and Diluted Loss per Common Share
The Company computes loss per common share using Accounting Standards Codification (“ASC”) 260 “Earnings Per Share.” Basic loss per share is computed by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding for the reporting period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts, such as stock options and warrants to issue common stock, were exercised or converted into common stock. Because the Company has incurred net losses and there are no dilutive potential common shares, basic and diluted loss per common share are the same.
Recent Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist, which is included in ASC Topic 740 (Income Taxes). ASU 2013-11 requires an entity to net its liability for unrecognized tax positions against a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. The provisions of this new guidance are effective for reporting periods beginning after December 15, 2013. The guidance is not expected to have a material impact on our statement of operations, financial position, or cash flows.
- 9 -

Table of Contents
In April 2014, the FASB issued ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”) which amended the FASB’s guidance for reporting discontinued operations and disposals of components of an entity under Accounting Standards Codification Subtopic 250-20. The guidance as amended by ASU 2014-08 raises the threshold for a disposal to qualify as a discontinued operation by requiring that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale be reported as such. The amendments also expand the disclosure requirements regarding the assets, liabilities, revenues and expenses of discontinued operations and add new disclosure requirements for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years beginning after December 15, 2014, and interim reporting periods within those years (early adoption is permitted only for disposals that have not been previously reported). The implementation of the amended guidance is not expected to have a material impact on the Company’s consolidated financial statements.
In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This ASU further clarified that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. ASU 2014-12 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.
3. FAIR VALUES OF FINANCIAL INSTRUMENTS
The Company measures certain financial liabilities (warrant liability, forward contract liability and derivative liabilities) at fair value on a recurring basis. The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:
Level 1 Measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the company has the ability to access at the measurement date.
Level 2 Measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
Level 3 Measurements are unobservable inputs.
Management believes that the carrying amounts of the Company’s financial instruments, consisting primarily of cash, accounts receivable, accounts payable and accrued expenses approximated their fair values at June 30, 2014 and December 31, 2013, due to their short-term nature.
Management also believes that the June 30, 2014 and December 31, 2013 interest rates associated with the notes payable approximates the market interest rates for these types of debt instruments and as such, the carrying amount of the notes payable approximates their fair value.
Common Stock Warrant Liability
The Company accounts for its common stock warrants under ASC 480, “Distinguishing Liabilities from Equity,” which requires any financial instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer’s equity shares, or is indexed to such an obligation, and it requires or may require the issuer to settle the obligation by transferring assets, would qualify for classification as a liability. The guidance required the Company’s outstanding warrants from private placements to be classified as liabilities and to be fair valued at each reporting period, with the changes in fair value recognized as a change in fair value of warranty liability in the Company’s consolidated statements of operations. Specifically, the warrants issued in connection with private placements grant the warrant holder certain anti-dilution protection providing exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share. Upon exercise or expiration of the warrants, the fair value of the warrant at that time will be reclassified to equity from a liability. The following table is a summary of the warrant liability activity measured at fair value using Level 3 inputs:
- 10 -

Table of Contents

|  | Warrant Liability |
Balance at December 31, 2013 |  | $ | 1,060,353 |
Granted |  |  | 167,532 |
Cancelled, forfeited or expired |  |  | (24,120 | )
Change in fair value of common stock warrants |  |  | (444,016 | )
Balance at June 30, 2014 (unaudited) |  | $ | 759,749 |

Forward contracts
As part of our 2013 private placement of common stock, the Company also agreed that the 38,462 shares of common stock included in the units are subject to increase and the $0.65 per share value is subject to decrease, in each case based on the level of the Company’s consolidated net revenues derived during our 2013 fiscal year (the “Make-Whole Adjustments”) (see Note 6 Common Stock for further details). The Company separately valued the forward contracts using Level 3 inputs. The fair value of the forward contracts of $115,767 was recorded as a liability and is included in accounts payable and accrued expenses on the Consolidated Balance Sheet as of December 31, 2013. The following table is a summary of the forward contract liability activity measured at fair value using Level 3 inputs:

|  | Forward Contract Liability |
Balance at December 31, 2013 |  | $ | 115,767 |
Granted |  |  | - |
Cancelled, forfeited or expired |  |  | (115,767 | )
Change in fair value |  |  | - |
Balance at June 30, 2014 (unaudited) |  | $ | - |

Derivative Liability
The derivative relates to the conversion feature into common stock at an initial rate of 2,000 common shares for each share of Series D Preferred Stock, subject to adjustment for certain anti-dilution protection and provides exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share (see Note 5 Redeemable Convertible Preferred Stock for further details). Management analyzed the terms of the conversion option and concluded that the conversion feature was derivative since it met the definition of a derivative and did not qualify for any of the exceptions. The Company therefore separately valued the derivative contracts using Level 3 inputs. The fair value of the derivatives was recorded as a derivative liability on the Consolidated Balance Sheet as of June 30, 2014 and December 31, 2013. The following table is a summary of the derivative liability activity measured at fair value using Level 3 inputs:

|  | Derivative Liability |
Balance at December 31, 2013 |  | $ | 312,088 |
Granted |  |  | - |
Cancelled, forfeited or expired |  |  |  |
Change in fair value |  |  | (126,691 | )
Balance at June 30, 2014 (unaudited) |  | $ | 185,397 |

- 11 -

Table of Contents
4. NOTES PAYABLE AND UNSECURED CONVERTIBLE DEBENTURES
The table below summarizes the Company’s notes payable and unsecured convertible debentures as of June 30, 2014:

|  | Related Party |  |  | Unrelated |  |  | Total |
Secured debt |  | $ | - |  |  | $ | 3,804,111 |  |  | $ | 3,804,111 |
Revolving credit facilities |  |  | 527,000 |  |  |  | 30,000 |  |  |  | 557,000 |
Other notes and debt |  |  | 440,000 |  |  |  | 42,068 |  |  |  | 482,068 |
Total notes payable |  | $ | 967,000 |  |  | $ | 3,876,179 |  |  | $ | 4,843,179 |
Unsecured convertible |  |  |  |  |  |  |  |  |  |  |  |
debentures, net of discount |  | $ | - |  |  | $ | 1,498,954 |  |  | $ | 1,498,954 |
Total debt |  | $ | 967,000 |  |  | $ | 5,375,133 |  |  | $ | 6,342,133 |

Unsecured Convertible Debentures
The Company completed various sales through private placements of senior convertible debentures to accredited investors. The debentures were convertible into shares of the Company’s common stock at an initial conversion price of $1.26 per share on an as converted basis, subject to adjustment. A consent and waiver was obtained from the majority of the Series A and C Preferred holders and a waiver was obtained from a majority of the Series B Preferred holders as required in the certificate of designation. From September 2012 through February 2013, the investors in our 2011 private placements consented to a partial anti-dilution adjustment in conversion price to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants. In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 2,072,654 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions
As part of the private placements, the investors received warrants to purchase shares of the Company’s common stock. The warrants were initially exercisable for a period of three years from the date of issuance at an initial exercise price of $1.512, subject to adjustment (see Note 6 Stock Warrants for further details). The investor may exercise the warrant on a cashless basis if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement. The outstanding warrants are subject to certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share. Accordingly, the fair value of the stock warrants is classified as a warrant liability on the accompanying condensed consolidated balance sheets as of June 30, 2014 and December 31, 2013.
As of June 30, 2014, we had the following unsecured convertible debentures outstanding to the following:

|  | Amount |  | Maturity Date |  | Interest Rate |  | # of Warrants |
HCI |  | $ | 1,150,000 |  | June 30, 2016 |  | 10.0% |  | 1,920,007 |
AQR |  |  | 200,000 |  | December 1, 2012 |  | 20.0% |  | 576,002 |
CNH |  |  | 100,000 |  | December 1, 2012 |  | 20.0% |  | 288,003 |
Coventry |  |  | 188,884 |  | April 1, 2016 |  | 16.0% |  | 575,999 |
Total |  |  | 1,638,884 |  |  |  |  |  | 3,360,011 |
Less debt discount |  |  | (139,930) |  |  |  |  |  |  |
Debentures, net |  | $ | 1,498,954 |  |  |  |  |  |  |

- 12 -

Table of Contents
HCI
The Company issued an aggregate total of $1,000,000 in senior convertible debentures to Hillair Capital Investment, Inc. (“HCI”) during the years ended December 31, 2012 and 2011. As of December 31, 2013, the debentures and related interest were past due. In February 2014, the Company entered into and Amended and Restated 10% Senior Convertible Debenture due June 30, 2016 with HCI in the amount of $1,150,000. The amendment relates to convertible debentures originally issued on May 16, 2011, August 22, 2011, November 30, 2011 and July 19, 2012 for an aggregate total of $1,000,000 in debentures. In addition to the extension of the maturity date, the interest rate was reduced from 16.0% to 10.0% per annum, and the conversion price was decreased from $0.90 to $0.75. As part of the agreement, the Company agreed to increase the principal amount of the debenture by $150,000 which represents eighteen months of interest due at the stated rate of 10% per annum. As a result, all interest accruable and payable between February 7, 2014 and August 8, 2015 is considered paid in full and satisfied. In addition, the Company issued 420,694 shares of common stock as payment of accrued interest of $252,417 at a rate of $0.60 per share. Further interest will not begin accruing until August 8, 2015. As part of the amendment, the exercise price of the related warrants was reduced from $0.90 to $0.75 resulting in the issuance of an additional 320,000 warrants per the warrant agreement terms.
Since the Company is experiencing financial difficulties and the debenture holder has granted a concession, the transaction met the requirement for troubled debt accounting treatment. Management compared the value of the accrued interest to the fair value of the common stock resulting in a gain on extinguishment of debt of $213,433 or $0.09 per common share.
AQR & CNH
In August 2011, the Company issued an aggregate total of $300,000 in senior convertible debentures to AQR Opportunistic Premium Offshore Fund, LP (“AQR”) and CNH Diversified Opportunities Master Account, LP (“CNH”). Due to our current financial condition, we did not make the periodic redemption payments of $75,000 due on June 1, 2012 and September 1, 2012 and the final payment due of $150,000 on or before December 1, 2012. Upon default, amounts owed become immediately payable to the debenture holder upon issuance of a notice of default. The debenture holders have issued a notice of default relating to our failure to make the periodic redemption payments on June 1, 2012 or September 1, 2012 or the final payment of $150,000 due on December 1, 2012 under the debenture agreement. In August 2013, the two holders filed a lawsuit against the Company for payment of past due amounts (See Note 9 Legal Matters for further details). In March 2014, the issuance of warrants to Series D Preferred Stock holders as part of the milestone provision with an effective conversion price of $0.40 per share qualified as a dilutive issuance per the terms of the convertible debenture. No waivers were obtained from the two debenture holders that were holding an aggregate total of $300,000 debentures. The anti-dilution adjustment reduced the conversion price from $0.50 to $0.40 per share. The amounts due on the debentures are classified as current at June 30, 2014 and December 31, 2013.
Coventry
On December 6, 2013, the Company settled a lawsuit with Coventry Enterprises, LLC (“Coventry”), a holder of $200,000 in convertible debentures issued in 2011. The terms of the settlement were before any application of any payments, we owe Coventry $280,679, which includes unpaid principal of $200,000, unpaid interest of $53,679 and unreimbursed attorney’s fees and costs of $27,000. The Company shall pay Coventry $280,679, plus interest at the rate of 16.0% per annum on the following schedule:

a) | $50,000 payable on or before December 6, 2013; and
b) | $10,000 payable on or before the first day of each month starting January 1, 2014 and continuing thereafter until the obligation is paid.

Based on the payment terms above, the obligation will be paid in full on Apri1 1, 2016. In March 2014, the issuance of warrants to Series D Preferred Stock holders as part of the milestone provision with an effective conversion price of $0.40 per share qualified as a dilutive issuance per the terms of the convertible. No waivers were obtained from Coventry debenture holders that were holding an aggregate total of $200,000 debentures. The anti-dilution adjustment reduced the conversion price on the debenture from $0.50 to $0.40 per share.
Interest expense related to the unsecured convertible debentures for the six months ended June 30, 2014 and 2013 was $138,911 and $438,213, respectively. Interest expense for the six months ended June 30, 2014 and 2013 included $108,571 and $242,934 at the stated rate, $27,603 and $175,745 in amortization of debt discount and $2,737 and $19,534 in amortization of deferred financing cost, respectively. The effective interest rate on convertible debentures was calculated as 17.2% and 29.6% for the six months ended June 30, 2014 and 2013, respectively.
As of June 30, 2014, the outstanding balance on unsecured convertible debentures, net of discounts was $1,498,954 with $396,664 classified as current. The outstanding debentures are convertible into an aggregate total of 2,755,544 common shares.
Secured Debt
In February 2013, the Company entered into a secured loan agreement with our primary wholesaler. Under the terms of this agreement, the Company received a one-year loan of $3,828,527 with an interest rate of 6.25% per annum, with interest payable monthly. Monthly payment requirements were $27,000 per month for four consecutive months, followed by four consecutive monthly payments of $37,000, followed by three consecutive monthly payments of $42,000, with remaining principal and interest due February 1, 2014. The proceeds from the note were simultaneously exchanged for $3,534,793 in outstanding vendor invoices and $293,734 in a secured note payable with the same primary wholesaler. The note is secured by all of the assets of the Company and its subsidiaries through UCC-1 filings. As part of the agreement, the Company is required to purchase a minimum of $500,000 in monthly purchases each month. The secured loan was subsequently extended with monthly payment requirements of $42,000, with remaining principal and interest due February 1, 2016.
- 13 -

Table of Contents
As of June 30, 2014, the outstanding principal balance on the note was $3,804,111. Due to our current financial condition, we have not made principal and interest payments in the amount of $359,243 as required by the agreement. In addition, we have not met our minimum monthly purchase requirements of $500,000 per month. In March 2014, we entered into a Forbearance Agreement with H.D. Smith Wholesale Drug Co. (“H.D. Smith”) in which the lender agreed to forbear from accelerating the outstanding balance of the Note and from instituting collection efforts from the date of the agreement through July 1, 2014 provided certain conditions are met, but not limited to Assured: (1) seeking new financing arrangements to improve its business viability, (2) providing financial statements to H.D. Smith on a monthly basis, (3) communicating with H.D. Smith regarding its business and financial position on a regular basis, and at the request of H.D. Smith, (4) making payments on the note when it is reasonably able to do so, (5) not entering into any agreements with any of their creditors that might impair their ability to perform under the agreement, and (6) ensuring that H.D. Smith is fully informed at all times of all matters relating to the operation of Assured’s businesses, including any planned changes in key personnel or material changes in the manner of operating such businesses. Due to our financial condition, we were unable to make the required payment on July 1, 2014 and we are currently in negotiations with the lender to restructure the terms of the note.
Revolving Credit Facilities
Brockington Securities, Inc. - Revolver
In March 2009, the Company entered into a Revolving Line of Credit Agreement with Brockington Securities Inc., a related party, for a credit limit of $300,000 with a term of one year bearing interest of 12% per annum. Under the terms of the agreement, the Company could request advanced payments from time to time, provided, however, any requested advance will not, when added to the outstanding principal advanced of all previous advances, exceed the credit limit. The Company could repay accrued interest and principal at any time, however no partial repayment would relieve the Company of the obligation of the entire unpaid principal together with any accrued interest and other unpaid charges. There are no financial covenants that the Company is required to maintain.
The agreement has been subsequently extended. The latest extension occurred in December 23, 2013, pursuant to a Modification and Extension Agreement to the Revolving Line of Credit Agreement dated March 10, 2009, in which the term of the loan was modified and the maturity date of the loan was extended to August 30, 2016 by mutual consent. On November 12, 2012, the credit limit was increased to $500,000, pursuant to an Amendment Agreement to the Revolving Line of Credit Agreement dated March 10, 2009. All additional terms of the loan remain unchanged and the Company was not in violation of any provisions of the loan agreement.
In May 2014, the credit limit was increased to $600,000 pursuant to an Amendment Agreement to the Revolving Line of Credit Agreement dated March 10, 2009.
As of June 30, 2014, the outstanding balance on the revolving line of credit was $527,000.
Third Coast Bank – Revolver
In December 2013, the Company entered into a revolving Promissory Note with Third Coast Bank SSB, for a credit limit of $30,000 with a term of one year bearing a variable interest rate of prime plus .500 percentage points with an interest rate floor of 5.00% per annum. The Promissory Note was guaranteed by Pinewood Trading Fund, LP, a related party.
As of June 30, 2014, the outstanding balance on the revolving line of credit was $30,000.
Other Notes and Debt
TPG, LLC
On December 15, 2006, the Company entered into a Share Purchase Agreement (the “Share Agreement”) with TPG, LLC pursuant to which the Company purchased 49 shares of common stock of Assured Pharmacies, Inc. (“API”) for 50,000 shares of common stock of the Company and a $460,000 note payable. The note is payable in $5,000 monthly installments through November 2007 and $15,000 monthly installments with the remaining balance due at maturity, February 15, 2009. The Company did not comply with the note terms due to its distressed financial condition.
- 14 -

Table of Contents
In December 2013, the parties entered into a Fourth Amendment to the Share Agreement between the Company and TPG, LLC. The maturity date of the note was extended from July 2013 to September 1, 2015. We issued 200,000 shares of the Company’s common stock and agreed to pay the remaining outstanding balance of $60,000 together with accrued interest at the rate of prime plus 2% per annum commencing from December 19, 2013, as follows:
(a) Six consecutive monthly installments of $2,000 on or before the 1st of each month commencing in December 2013 through May 2014.
(b) Sixteen consecutive monthly installments of $3,000 on or before the 1st of each month, commencing in June 2014 through September 2015.
As of June 30, 2014, the outstanding principal balance on the note was $42,068.
Pinewood Notes
In January 2014, we entered into a $200,000 note agreement with Pinewood Trading Fund, LP (“Pinewood”), a related party with a maturity date of January 28, 2016. The note bears an interest rate of 16% per annum payable on July 1 and January 1 of each calendar year. Unless otherwise instructed by Pinewood, the accrued and unpaid interest shall be paid in duly authorized, validly issued, fully paid and non-assessable shares of the Company’s common stock. As of June 30, 2014, the outstanding balance on the note was $214,078, which includes $14,078 in accrued but unpaid interest.
In February and March 2014, the Company entered into short term promissory notes with Pinewood, a related party for an aggregate total of $240,000. The short term notes bear an interest rate of 12.0% per annum and mature on April 30, 2014.
As of June 30, 2014, the aggregate outstanding balance on the notes was $275,058, which includes $25,058 in accrued but unpaid interest. As of August 14, 2014, the Company has not repaid the short term promissory note and is currently in negotiations to restructure the repayment terms of the note.
5. REDEEMABLE CONVERTIBLE PREFERRED STOCK
On September 1, 2013, the Company entered into a Stock Purchase Agreement (“SPA”) with Pinewood Trading Fund, LP, (“Pinewood”) an existing shareholder (related party) to purchase up to 3,000 shares of Series D Convertible Preferred Stock at $1,000 per share.
In November 2013, the Company designated 15,000 shares to Series D Preferred Stock. The Series D Preferred rank senior to the Series A Preferred, Series C and Series B Preferred which ranks senior to the Company’s common stock with respect to the payment of any dividends and amounts upon liquidation or dissolution.
Pinewood must approve certain corporate actions of the Company, regardless of the total Common Stock votes for or against such actions. Such actions include, but are not limited to: any increase or decrease in the authorized number of shares of Common Stock or Preferred Stock; the delisting of any of the Company’s securities from the OTCQB or any national securities exchange; any redemption or repurchase with respect to the Common Stock or Preferred Stock; any liquidation, dissolution or winding-up of the business and affairs of the Company; any material modification or deviation from the Company’s annual business plan and operating budget; any payment or declaration of a dividend or other distribution on any shares of Common Stock or Preferred Stock made by the Board of Directors; and any change in the principal business of the Company. In addition to the foregoing, holders of the Series D Preferred Stock have the right to elect one director of the Company so long as at least 35% of the Series D Preferred Stock are issued and outstanding. Each share of Series D Preferred Stock is convertible into 2,000 shares of the Company’s common stock.
In addition, Pinewood may, but is not obligated to, nominate one Director to add to the Company’s existing Board currently comprised of four people (for a total of five directors). The Company is further restricted, precluded, and prohibited from increasing the number of directors beyond four or five should Pinewood elect to nominate a director) without the consent of Pinewood. This gives Pinewood the ability without restriction or notice to install a board member at any time, subject to applicable law and the Company’s charter document, at Pinewood’s sole discretion.
Preferred Stock Private Placements
In November 2013, the Company issued 800 shares of Series D Preferred Stock to Pinewood Trading Fund, LP, a related party, for $1,000 per share for an aggregate purchase price of $800,000. For each share of Series D Preferred Stock purchased, two five-year warrants were issued as follows: (i) a Series A Warrant to purchase 2,000 shares of the Company’s common stock; and (ii) a Series B Warrant to purchase 2,000 shares of common stock.
- 15 -

Table of Contents
In December 2013, the Company issued 200 shares of Series D Preferred Stock to Pinewood Trading Fund, LP, a related party for $1,000 per share for an aggregate purchase price of $200,000. For each share of Series D Preferred Stock purchased, two five-year warrants were issued as follows: (i) a Series A Warrant to purchase 2,000 shares of the Company’s common stock; and (ii) a Series B Warrant to purchase 2,000 shares of common stock.
In December 2013, the Company issued 20 shares of Series D Preferred Stock to Craig Eagle, a director of the Company, for $1,000 per share for an aggregate purchase price of $20,000. For each share of Series D Preferred Stock purchased, two five-year warrants were issued as follows: (i) a Series A Warrant to purchase 2,000 shares of the Company’s common stock; and (ii) a Series B Warrant to purchase 2,000 shares of common stock.
In December 2013, the Company issued 50 shares of Series D Preferred Stock to an existing investor for $1,000 per share for an aggregate purchase price of $50,000. For each share of Series D Preferred Stock purchased, two five-year warrants were issued as follows: (i) a Series A Warrant to purchase 2,000 shares of the Company’s common stock, par value $0.001 per share; and (ii) a Series B Warrant to purchase 2,000 shares of common stock.
As part of the private placements, the investors received warrants to purchase an aggregate of 4,280,000 shares of the Company’s common stock. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.50, subject to adjustment. The investor may exercise the warrant on a cashless basis if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement. The outstanding warrants are subject to certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share. Accordingly, the stock warrants are classified as a warrant liability on the accompanying consolidated balance sheets as of June 30, 2014 and December 31, 2013.
The Securities Purchase Agreement (“SPA”) contains a Milestone Adjustment provision. If by March 1, 2014, the Company’s income, on a Special Adjustment Basis (“SAB”) for the period beginning on January 1, 2014 and ending on February 28, 2014 (the “Measurement Period”) is not positive, on a SAB, then the Company will immediately issue (after the cash-flow on SAB calculation is final) to Investors, pro rata based on their ownership of Series D Preferred Stock, an aggregate additional (i) 2,400 shares of Series D Preferred Stock and (ii) for each share of Series D Preferred Stock issued above, one Series A Warrant and one Series B Warrant; and the exercise price of all warrants then held by the Investors (including the Warrants and any previously issued warrants of the Company then held by Investors) shall be reduced to $0.40, which number shall be subject to adjustment for issuances or circumstances following the Closing Date that would otherwise result in an adjustment to the exercise price of any such warrant In addition, if the milestone adjustment is required, Pinewood shall be entitled thereafter to elect a majority of the Board of Directors, to be accomplished in any manner that Pinewood deems most expedient and in compliance with applicable laws and the Company’s charter documents. The SAB shall be based on the trailing two month net income of the Company, excluding stock-based compensation and non-cash other (non-operating) expenses. The Company believed that it could achieve this goal by March 1, 2014, but it did not. The milestone adjustment feature is not free standing from the Series D Preferred Stock and will not be separately classified from the preferred security. The fair value of the milestone adjustment will be recorded if the milestone adjustment is required.
In March 2014, the Company did not meet the requirements of the Milestone Provision of the Series D Preferred of reaching positive net income on a Special Adjusted Basis (“SAB”) for the trailing two months ending February 2014. As a result, the Company issued an additional 856 shares of Series D Preferred stock and additional 3,424,000 warrants to purchase common stock at $0.40 to the Series D holders. In addition, the exercise price on warrants to purchase an aggregate total of 4,280,000 common shares has been reduced to $0.40 per share. Pinewood is also entitled to elect a majority of the Board of Directors, to be accomplished in any manner that it deems most expedient and in compliance with applicable laws and the Company’s charter documents. The Company recorded a $662,057 milestone adjustment for preferred stock, which is a deemed dividend distribution for accounting purposes.
The SPA also contains a mandatory redemption provision. If, as of January 1, 2016: (i) the Common Stock has traded on the 20 trading days prior to January 1, 2016 at an average closing price of less than $1.00; or (ii) the Common Stock has had during the 30 trading days prior to January 1, 2016 an average daily trading volume of less than 70,000 shares, then the Company shall immediately, to the extent it may lawfully do so, redeem all outstanding shares of Series D Preferred Stock at a purchase price of $2,000 per share, plus a cumulative preference of 8% per annum compounded annually. Such redemption shall have preference over redemption of any other class of shares.
If the mandatory redemption does not occur within 10 business days, then payments to the Convertible Debt holders shall be subordinated, pursuant to that certain Subordination Agreement executed by the Convertible Debt holders, until the shares of Series D Preferred Stock are redeemed. If the mandatory redemption does not occur within 60 business days, Pinewood shall have the right to elect a majority of the Company’s Board of Directors, and may seek a sale of the Company, subject to the determination of the Board of Directors.
- 16 -

Table of Contents
Failure to immediately redeem the Series D Preferred shares will, at Pinewood’s election, result in the Company immediately issuing to Pinewood an additional (i) 2,400 shares of Series D Preferred Stock and (ii) for each share of Series D Preferred Stock issued above, one Series A Warrant and one Series B Warrant, and the exercise price of all warrants then held by Pinewood (including the Warrants and any previously issued warrants of the Company then held by Investor) shall be reduced to $0.10 (ten cents) (which number shall be subject to adjustment for issuances of circumstances following the Closing that would otherwise result in an adjustment to the exercise price of any such warrant).
The mandatory redemption feature is not freestanding from the Series D Preferred stock and will not be separately classified from the preferred security. Since the mandatory redemption is conditioned upon the Company’s stock price and volume which are note solely within the control of the issuer and the price and date are fixed, the Series D Preferred are classified as temporary equity on the consolidated balance sheets as of June 30, 2014 and December 31, 2013. Management analyzed the terms of the mandatory redemption feature and evaluated whether it was probable that the instruments will become redeemable and concluded that it was probable that the instruments will become redeemable. Management elected to recognize changes in the redemption value immediately as they occur and adjusted the redemption value as if it were also the redemption date for the instrument. As a result, management increased the carrying value of the preferred instrument by $2,192,588 for the redemption feature on preferred stock in the year ended December 31, 2013. The redemption feature on preferred stock is a deemed dividend distribution for accounting purposes.
The Series D Preferred stock includes a conversion feature in which each share of Series D Preferred Stock is initially convertible into 2,000 shares of the Company’s common stock. Management analyzed the terms of the conversion option and concluded that the conversion feature was derivative since it met the definition of a derivative and did not qualify for any of the exceptions. The initial aggregate fair value of the derivatives was determined to be $238,171 which was recorded as a derivative liability on the Consolidated Balance Sheet as of December 31, 2013 (See Note 3 Derivative Liability for further details).
The Company allocated the proceeds of these preferred issuances, by first allocating the proceeds to warrant liability and derivative liability based on fair value and then allocated the remaining residual proceeds, net of closing costs to the preferred stock security.
As of June 30, 2014, an aggregate total of 1,926 Series D Shares had been issued, which is convertible into 3,852,000 shares of common stock.
6. EQUITY TRANSACTIONS
Convertible Preferred Stock Series – A, B & C
The Company has authorized 5,000,000 shares of preferred stock, with 2,830 shares designated to Series A Preferred and 7,745 shares designated to Series B Preferred and 813 shares designated to Series C Preferred.
The Series A Preferred and Series C Preferred rank senior to the Series B Preferred which ranks senior to the Company’s common stock with respect to the payment of any dividends and amounts upon liquidation or dissolution. Except as required by law, the shares of preferred stock shall be voted together with the shares of common stock and not as a separate class. In addition, so long as 35% of the aggregate amount of the shares of Series A Preferred and Series C Preferred are outstanding, the holders of the outstanding shares voting together as a separate class are entitled to elect up to four directors to the Board and separately vote on a number of defined material actions typically requiring Board approval. Respectively, holders of shares of Series A, B and C Preferred have anti-dilution protections for sale of stock below conversion rate and stock splits and other similar pro rata events.
Series A and Series B
In June 2009, in a private placement pursuant to the Purchase Agreement dated February 9, 2009, with Mosaic, a related party (see Note 8 for further details), the Company agreed to sell 1,330 shares of its Series A Preferred and common stock purchase warrants to purchase an aggregate of 1,083,334 shares of its common stock for an aggregate purchase price of $1.3 million, of which $750,000 was paid by the cancellation of secured indebtedness of the Company owed to MFS, with the remaining $580,000 to be paid in cash. As a condition of closing of this transaction, the outstanding principal balance related to Short Term Notes and Unsecured Debentures of $7.7 million was exchanged for 7,720 shares of Series B Preferred.
As of June 30, 2014, the Company issued a total of 559 shares of Series A Preferred for $558,500 to Mosaic under the 2009 Securities Purchase agreement. Each share of Series A Preferred is convertible into 1,111 shares of common stock. As of June 30, 2014, no shares of Series A Preferred issued to Mosaic have been converted into common stock.
Series C
In May 2010, we filed a Certificate of Designation to designate 813 shares of the Company’s Preferred stock in Series C Preferred. The rights of the Series C Preferred are identical to those of the Series A Preferred. Subsequently, the Company issued 813 shares of the Company’s Series C Preferred at a price of $1,000 per share to an existing vendor in exchange for extinguishment of $300,000 in vendor’s secured payable and additional consideration in the form of a modification in vendor terms that are favorable to the Company and additional debt financing at terms that are significantly below market for the Company.
- 17 -

Table of Contents
The table below summarizes the Company’s outstanding convertible preferred stock as of June 30, 2014 and December 31, 2013:

| June 30, 2014 |  | December 31, 2013 |
Convertible Preferred Stock |  | Number of Preferred Shares |  | Number of Common Shares if Converted |  | Weighted Average Conversion Price |  | Number of Preferred Shares |  | Number of Common Shares if Converted |  | Weighted Average Conversion Price |
Series A Preferred |  |  | 1,466 |  | 1,629,006 |  | $ | 0.90 |  | 1,466 |  | 1,629,006 |  | $ | 0.90 |
Series B Preferred |  |  | 5,124 |  | 5,693,344 |  | $ | 0.90 |  | 5,124 |  | 5,693,344 |  | $ | 0.90 |
Series C Preferred |  |  | 813 |  | 902,778 |  | $ | 0.90 |  | 813 |  | 902,778 |  | $ | 0.90 |
Total |  |  | 7,403 |  | 8,225,128 |  | $ | 0.90 |  | 7,403 |  | 8,225,128 |  | $ | 0.90 |

Common Stock
In January 2014, in accordance with the Make-Whole provision in our 2013 private placement of our common stock, we issued 826,907 shares of common stock to the eight investors that participated in the private placement. Our consolidated net revenues for the fiscal year ending December 31, 2013 were $7,463,113 which included $2,270,536 in revenues from discontinued operations. Since the net revenues are below the Make-Whole Adjustment minimum threshold of $17,250,000, we were required to issue additional common stock in accordance with the agreement.
Stock Warrants
Historically, the Company issued common stock warrants to investors and placement agents in private placements of convertible debentures, common stock and preferred stock from 2009 to 2013. The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share. Accordingly, the stock warrants are classified as a warrant liability on the accompanying condensed consolidated balance sheets as of June 30, 2014 and December 31, 2013.
The estimated fair value of these warrants was determined using a lattice stock option pricing model on the issuance date, assuming that there will be no dividends, using the applicable exercisable periods, a risk-free interest rate, and an expected volatility.
In February 2014, an additional 320,000 warrants were issued to HCI, a holder of 1,600,007 warrants as part of the modification and extension transaction (See Note 4 HCI for further details).
In March 2014, the Company did not meet the requirements of the Milestone Provision of the Series D Preferred of reaching positive net income on a Special Adjusted Basis (“SAB”) for the trailing two months ending February 2014. As a result, the Company issued an additional 3,424,000 warrants to purchase common stock at $0.40 to the Series D holders. In addition, the exercise price on warrants to purchase an aggregate total of 4,280,000 common shares has been reduced to $0.40 per share.
In March 2014, the issuance of warrants to Series D preferred stock with an effective exercise price of $0.40 per share qualified as a dilutive issuance per the terms of the warrant. (See Note 5 Preferred Stock Private Placements for further details). No waivers were obtained from three debenture holders that were holding an aggregate total of 1,440,004 warrants regarding the dilutive issuance. The anti-dilution adjustment reduces the exercise price of the existing warrants from $0.50 to $0.40 and requires the issuance of an additional 360,001 warrants to the three investors.
In March 2014, the issuance of warrants to Series D preferred stock with an effective exercise price of $0.40 per share qualified as a dilutive issuance per the terms of the warrant. (See Note 5 Preferred Stock Private Placements for further details). No waivers were obtained from eleven warrant holders that participated in our 2013 private placement of common stock that were holding an aggregate total of 2,538,000 warrants regarding the dilutive issuance. The anti-dilution adjustment reduces the exercise price of the existing warrants from $0.50 to $0.40 and requires the issuance of an additional 634,502 warrants to the eight investors and three placement agents.
- 18 -

Table of Contents
Expected Stock Volatility
Volatility is a measure of the tendency of investment returns to vary around a long-term average rate. Historical volatility is an appropriate starting point for setting this assumption. Companies should also consider how future experience may differ from the past. This may require using other factors to adjust historical volatility, such as implied volatility, peer-group volatility and the range and mean-reversion of volatility estimates over various historical periods. The peer-group utilized consisted of six companies in 2014 and in 2013, in the same or similar industries as the Company. In addition, if a best estimate cannot be made, management should use the mid-point in the range of reasonable estimates for volatility. The Company estimates the volatility of its common stock in conjunction with the Company’s issuance of financing instruments and volatility is calculated utilizing the historical and estimated future volatility of the Company and its peer-group.
Risk-Free Rate of Return
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option/warrant.
Expected Dividends
The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. Consequently, it uses an expected dividend yield of zero.
Expected Term
The Company uses the related exercise period of the warrant or option as the expected term.
A summary of the warrants issued in connection with financing transactions is presented in the table below:

|  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding and Exercisable at December 31, 2013 |  |  | 14,394,914 |  |  | $ | 0.58 |
Granted |  |  | - |  |  | $ | - |
Exercised |  |  | - |  |  | $ | - |
Cancelled, forfeited or expired |  |  | (719,999) |  |  | $ | 0.40 |
Anti-dilution adjustments: |  |  |  |  |  |  |  |
Initial grant |  |  | (9,858,011) |  |  | $ | 0.56 |
Initial grant re-pricing |  |  | 9,858,011 |  |  | $ | 0.46 |
Additional warrants granted |  |  | 4,738,503 |  |  | $ | 0.42 |
Outstanding and Exercisable at June 30, 2014 (unaudited) |  |  | 18,413,418 |  |  | $ | 0.46 |

The following table summarizes information about warrants outstanding and exercisable as of June 30, 2014:

|  | Outstanding |  | Exercisable |
Exercise Price |  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life (Years) |  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life (Years) |
$ | 0.09 |  | 1,083,334 |  | $ | 0.09 |  | 5.00 |  | 1,083,334 |  | $ | 0.09 |  | 5.00 |
$ | 0.40 |  | 11,956,508 |  | $ | 0.40 |  | 3.32 |  | 11,956,508 |  | $ | 0.40 |  | 3.32 |
$ | 0.60 |  | 3,453,569 |  | $ | 0.60 |  | 5.17 |  | 3,453,569 |  | $ | 0.60 |  | 5.17 |
$ | 0.75 |  | 1,920,007 |  | $ | 0.75 |  | 2.30 |  | 1,920,007 |  | $ | 0.75 |  | 2.30 |
|  |  | 18,413,418 |  | $ | 0.46 |  | 3.87 |  | 18,413,418 |  | $ | 0.46 |  | 3.87 |

- 19 -

Table of Contents
7. STOCK-BASED COMPENSATION
Restricted Shares of Common Stock
During the six months ended June 30, 2013, the Company issued 220,000 restricted share grants to consultants and directors as compensation for services, the Company did not issue restricted share grants in the three months ended June 30, 2014.
The Company recognized $99,937 and $175,500 in stock compensation expense related to restricted share grants and is included in selling, general and administrative expenses in the consolidated statement of operations for the three and six months ended June 30, 2014, and 2013, respectively. As of June 30, 2014, there was no unrecognized compensation cost related to restricted share awards.
Stock Warrants
Historically, the Company issued warrants to purchase common stock to employees and consultants as compensation for services. The Company amortizes the fair value of the stock warrants to expense ratably over the related service period.
The following table summarizes the warrants outstanding and the number of shares of common stock subject to exercise as of June 30, 2014 and December 31, 2013:

|  | Employees |  |  | Services |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Shares |  |  | Weighted Average Exercise Price |
Outstanding and Exercisable at December 31, 2013 |  |  | - |  |  | $ | - |  |  |  | 850,000 |  |  | $ | 0.96 |
Warrants granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Warrants exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Warrants expired/cancelled |  |  | - |  |  |  | - |  |  |  | (20,000) |  |  |  | 1.80 |
Outstanding and Exercisable at June 30, 2014 (unaudited) |  |  | - |  |  | $ | - |  |  |  | 830,000 |  |  | $ | 0.93 |

The following table summarizes information about stock warrants outstanding and exercisable as of June 30, 2014:

|  | Outstanding |  | Exercisable
Range of Exercise Price |  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life (Years) |  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life (Years)
$0.65 |  | 600,000 |  | $ | 0.65 |  | 3.82 |  | 600,000 |  | $ | 0.65 |  | 3.82
$1.52 - $1.80 |  | 230,000 |  | $ | 1.68 |  | 2.16 |  | 230,000 |  | $ | 1.68 |  | 2.16
|  | 830,000 |  | $ | 0.93 |  | 3.36 |  | 830,000 |  | $ | 0.93 |  | 3.36

- 20 -

Table of Contents
Stock compensation expense related to stock warrants for the six months ended June 30, 2014 and 2013 was $0 and $174,726, respectively. As of June 30, 2014, there was no unrecognized compensation cost related to stock warrant awards.
Stock Options
In May 2012, we adopted the Assured Pharmacy, Inc. 2012 Incentive Compensation Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan is intended to provide incentives that will attract and retain the best available directors, employees and appropriate third parties who can provide us with valuable services. These purposes may be achieved through the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock awards, performance stock awards and phantom stock awards.
The 2012 Incentive Plan permits the grant of awards that may deliver up to an aggregate of 1,667,667 shares of common stock, further subject to limits on the number of shares that may be delivered pursuant to incentive stock options, on the shares that may be delivered on the awards to any individual in a single year and on the number of shares that may be delivered on certain awards that are performance-based awards, within the meaning of Section 162(m) of the Internal Revenue Code. Awards may vest, in time, upon the occurrence of one or more events or by the satisfaction of performance criteria, or any combination. To the extent that awards are performance based, they may be based on one or more criteria, including (without limitation) earnings, cash flow, revenues, operating income, capital reissues, or other quantifiable company, customer satisfaction or market data, or any combination. In addition to common stock, awards may also be made in similar securities whose value is derived from our common stock.
Awards with respect to which grant, vesting, exercisability or payment depend on the achievement of performance goals and awards that are options or stock appreciation rights granted to officers and employees will be intended to satisfy the requirements for “performance-based compensation” under Section 162(m) of the Internal Revenue Code. The 2012 Incentive Plan will be administered by the board of directors.
At June 30, 2014, all options outstanding and exercisable are out of the money and, accordingly, their intrinsic value is zero.
The following table summarizes the stock options outstanding and the number of shares of common stock subject to exercise as of June 30, 2014 and December 31, 2013:

|  | Options Outstanding |  |  | Options Exercisable |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Shares |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2013 |  |  | 1,840,556 |  |  | $ | 0.66 |  |  |  | 1,840,556 |  |  | $ | 0.66 |
Options granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options vested |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options expired/cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at June 30, 2014 (unaudited) |  |  | 1,840,556 |  |  | $ | 0.66 |  |  |  | 1,840,556 |  |  | $ | 0.66 |

The following table summarizes information about stock options outstanding and exercisable as of June 30, 2014:

|  |  | Outstanding |  |  | Exercisable |
Exercise Price |  |  | Stock Options Outstanding |  |  | Weighted Average Exercise Price Per Share |  |  | Weighted Average Remaining Contractual Term in Years |  |  | Stock Options Exercisable |  |  | Weighted Average Exercise Price Per Share |  |  | Weighted Average Remaining Contractual Term in Years |
$ | 0.60 |  |  |  | 525,000 |  |  | $ | 0.60 |  |  |  | 7.86 |  |  |  | 525,000 |  |  | $ | 0.60 |  |  |  | 7.86 |
$ | 0.68 |  |  |  | 1,305,556 |  |  | $ | 0.68 |  |  |  | 6.75 |  |  |  | 1,305,556 |  |  | $ | 0.68 |  |  |  | 6.75 |
$ | 1.26 |  |  |  | 10,000 |  |  | $ | 1.26 |  |  |  | 5.70 |  |  |  | 10,000 |  |  | $ | 1.26 |  |  |  | 5.70 |
|  |  |  |  | 1,840,556 |  |  | $ | 0.66 |  |  |  | 7.06 |  |  |  | 1,840,556 |  |  | $ | 0.66 |  |  |  | 7.06 |

- 21 -

Table of Contents
The Company recorded stock-based compensation expense related to stock options for the three months ended June 30, 2014 and 2013 of $0 and $76,552, respectively, which is reflected in selling, general and administrative expense in the condensed consolidated statement of operations. As of June 30, 2014, there was no unrecognized compensation cost related to stock option awards.
The Company has reserved at total of 2,690,556 shares of its common stock for incentive stock option and warrant awards outstanding to employees and consultants and an additional 1,142,667 shares of common stock for unissued options per the 2012 Incentive Plan. The Company does not expect to repurchase shares during the year 2014.
8. RELATED PARTY TRANSACTIONS
Transactions with related parties and their affiliates are made in the ordinary course of business on substantially the same terms and conditions, including interest rates and collateral, as those prevailing at the same time for comparable transactions with other unaffiliated third parties, and do not, in the opinion of management, involve more than normal credit risk or present other unfavorable features. Related parties include the following:

● | Robert DelVecchio, an officer and a member of the board of directors of the Company and his affiliate Brockington Securities, Inc. (collectively, “DelVecchio”).
● | Pinewood Trading Fund, LP and its managing partner Jack E. Brooks, who beneficially own approximately 93.5% of the Company’s Series D Preferred Stock and 11% of the Company’s Series B Preferred as of June 30, 2014.

Outstanding debt to related parties consisted of the following at June 30, 2014:

|  | DelVecchio |  |  | Pinewood |  |  | Total |
Notes payable - revolving |  | $ | 527,000 |  |  | $ | - |  |  | $ | 527,000 |
Notes payable |  |  | - |  |  |  | 440,000 |  |  |  | 440,000 |
Accrued interest |  |  | 33,974 |  |  |  | 39,136 |  |  |  | 73,110 |
|  | $ | 560,974 |  |  | $ | 479,136 |  |  | $ | 1,040,110 |

9. COMMITMENTS AND CONTINGENCIES
Legal Matters
Providing pharmacy services entails an inherent risk of medical and professional malpractice liability. The Company may be named as a defendant in such lawsuits and become subject to the attendant risk of substantial damage awards. The Company believes it possesses adequate professional and medical malpractice liability insurance coverage. There can be no assurance that the Company will not be sued, that any such lawsuit will not exceed our insurance coverage, or that it will be able to maintain such coverage at acceptable costs and on favorable terms.
From time to time, we may be involved in various claims, lawsuits, and disputes with third parties, actions involving allegations of discrimination or breach of contract actions incidental to the normal operations of the business. Providing pharmacy services entails an inherent risk of medical and professional malpractice liability. We may be named as a defendant in such lawsuits and thus become subject to the attendant risk of substantial damage awards. We believe that we have adequate professional and medical malpractice liability insurance coverage. There can be no assurance, however, that we will not be sued, that any such lawsuit will not exceed our insurance coverage, or that we will be able to maintain such coverage at acceptable costs and on favorable terms.
On March 18, 2011, a lawsuit was filed by Tim Chandler, Jodi Marshall, Christie Garner, the Estate of Thomas Pike, Jr., and Angie Hernandez in the Circuit Court of the State of Oregon for Multnomah County against Payette Clinics, P.C., Scott Pecora, Kelly Bell, Penny Steers and our wholly-owned subsidiaries, Assured Pharmacies Northwest, Inc. and Assured Pharmacy Gresham, Inc. The lawsuit arose from allegations that nurse practitioners at Payette Clinics, P.C. prescribed the five plaintiffs controlled substances in amounts that were excessive under the appropriate medical standard of care. Only one of the plaintiffs, Tim Chandler, brought claims against our subsidiaries. Mr. Chandler’s claims against our subsidiaries were for negligence on the basis of allegations that our subsidiaries knew or had reason to know that the prescriptions fell below the standard of care applicable to the prescription of such controlled substances but nonetheless filled the prescriptions. The plaintiffs, as a whole, submitted a prayer for $7,500,000 in damages. Mr. Chandler only seeks “an amount to be proven at trial” for noneconomic damages and unnecessary expenses. Management believes that the allegations against our subsidiaries are without merit and plans to vigorously defend this claim. We have $2,000,000 in insurance coverage for claims relating to pharmacy negligence. This lawsuit has been stayed as a result of a co-defendant in this lawsuit (Payette Clinics, P.C.) having filed for bankruptcy. The bankruptcy has since been discharged and the automatic stay lifted. The case recently came out of abatement and is set for a two-week trial beginning March 16, 2015. The Company has denied any liability and is vigorously defending against this action.
- 22 -

Table of Contents
On August 23, 2013, AQR Opportunistic Premium Offshore Fund, LP and CNH Diversified Opportunities Master Account, LP filed a lawsuit against Assured Pharmacy in the Supreme Court of the State of New York. Plaintiffs submitted a Motion for Summary Judgment in Lieu of Complaint against defendants to recover money allegedly owed by Assured Pharmacy, Inc. under two 16% Convertible Debentures totaling $300,000 and issued in and around 2011 in a private placement. On September 19, 2013, Assured removed the action to the United States District Court for the Southern District of New York. All scheduled briefing regarding Plaintiffs’ Motion for Summary Judgment in Lieu of Complaint was fully submitted to the Court as of October 18, 2013, and the parties are currently awaiting a decision and Order. Assured plans to vigorously defend against Plaintiffs’ claims.
On December 16, 2013 a lawsuit was filed by Ann Raffaele, in the Circuit Court of the State of Oregon for Multnomah County against Assured Pharmacy, Inc. and our wholly-owned subsidiaries, Assured Pharmacies Northwest, Inc. and Assured Pharmacy Gresham, Inc. The lawsuit arises from allegations of medical negligence by Dr. Edward Goering, D.O. and Assured Pharmacy. The plaintiff submitted a prayer for $1,500,000 in damages. Management believes that the allegations against the Company are without merit and plans to vigorously defend against this claim. We have $2,000,000 in insurance coverage for claims relating to pharmacy negligence.
On February 19, 2014, a lawsuit was filed by JS Barkats PLLC, in the Supreme Court of The State of New York, County of New York against Assured Pharmacy, Inc. and Robert DelVecchio, our Chief Executive Officer. The lawsuit arises from allegations of failing to remit legal fees due under written retainer agreements of $134,300 and failing to deliver 500,000 freely traded shares of the Company’s common stock pursuant to one of the retainer agreements. Defendants filed a Verified Answer on March 21, 2014. On June 19, 2014, the parties entered into a Preliminary Conference Order setting the timing and sequence of discovery in the action. A Compliance Conference has been scheduled for September 4, 2014. Management believes that the allegations against the Company are without merit and plans to vigorously defend against this claim.
Accounts Receivable Sold with Recourse
In March 2014, the Company entered into a $600,000 Non-Disclosable Revolving Line of Credit Loan with Third Coast Bank SSB due on March 25, 2015. The loan is not subject to an interest rate, but is subject to service charges based on the amount of funds advanced. In June 2014, the Company entered into a modification of the $600,000 Non-Disclosable Revolving Line of Credit due March 25, 2015 whereby the Revolving Line of Credit was increased to $1,200,000 and the maturity date was extended to June 5, 2015. As of June 30, 2014, the Company had a net balance of $561,234 in accounts receivable that were sold with recourse, net of reserves required per the agreement.
10. SUPPLEMENTAL CASH FLOW FINANCIAL INFORMATION
The supplemental disclosure requirements for the statements of cash flows are as follows:

|  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Cash paid during the period for: |  |  |  |  |  |
Interest |  | $ | 122,476 |  |  | $ | 183,912 |
Non-cash investing and financing activities during the period: |  |  |  |  |  |  |  |
Reissuance of stock warrants in refinancing |  | $ | 167,532 |  |  | $ | - |
Cancellation of stock warrants in refinancing |  | $ | (24,120 | ) |  | $ | - |
Common stock issued for payment of forward contract |  | $ | 115,767 |  |  | $ | - |
Series D preferred stock issued as payment for milestone adjustment |  | $ | 662,057 |  |  | $ | - |
Conversion of Series B Preferred stock into common |  | $ | - |  |  | $ | 185,000 |
Conversion of vendor payable into secured note payable |  | $ | - |  |  | $ | 3,534,793 |
Conversion of secured notes payable in refinancing |  | $ | - |  |  | $ | 293,734 |
Common stock warrants issued with common stock |  | $ | - |  |  | $ | 243,055 |
Common stock warrants issued for placement fees |  | $ | - |  |  | $ | 32,845 |
Common stock warrants issued for Series D preferred stock |  | $ | - |  |  | $ | - |
Forward contract issued with common stock |  | $ | - |  |  | $ | 233,131 |
Common stock issued for payment of interest in refinancing |  | $ | 63,104 |  |  | $ | - |

- 23 -

Table of Contents
11. LOSS PER COMMON SHARE
The following is a reconciliation of the numerators and denominators of the basic and diluted loss per common share computations for the years ended:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013 |
Numerator for basic and diluted loss per common share: |  |  |  |  |  |  |  |  |  |  |  |
Net loss to common stockholders from continuing operations |  | $ | (538,735 | ) |  | $ | (1,348,100 | ) |  | $ | (1,316,105 | ) |  | $ | (2,473,318 | )
Net loss from discontinuing operations |  | $ | (9,519 | ) |  | $ | (499,423 | ) |  | $ | (19,464 | ) |  | $ | (507,217 | )
Net loss to common stockholders |  | $ | (548,254 | ) |  | $ | (1,847,523 | ) |  | $ | (1,335,569 | ) |  | $ | (2,980,535 | )
Denominator for basic and diluted loss per common share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted Average Number of Shares Outstanding |  |  | 11,503,294 |  |  |  | 5,817,053 |  |  |  | 11,414,481 |  |  |  | 5,361,577 |
Basic and diluted loss per common share from continuing operations |  | $ | (0.05 | ) |  | $ | (0.23 | ) |  | $ | (0.12 | ) |  | $ | (0.46 | )
Basic and diluted loss per common share from discontinued operations |  | $ | - |  |  | $ | (0.09 | ) |  | $ | - |  |  | $ | (0.09 | )
Basic and diluted loss per common share |  | $ | (0.05 | ) |  | $ | (0.32 | ) |  | $ | (0.12 | ) |  | $ | (0.56 | )

Due to their anti-dilutive effect, the potential common shares have been excluded from the computation of diluted loss per share:

|  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Warrants |  |  | 19,243,418 |  |  |  | 7,504,189 |
Stock options |  |  | 1,840,556 |  |  |  | 1,840,556 |
Convertible notes |  |  | 2,755,544 |  |  |  | 3,295,322 |
Series A Preferred |  |  | 1,629,006 |  |  |  | 1,629,006 |
Series B Preferred |  |  | 5,693,344 |  |  |  | 5,776,667 |
Series C Preferred |  |  | 902,778 |  |  |  | 902,778 |
Series D Preferred |  |  | 3,852,000 |  |  |  | - |
|  |  | 35,916,646 |  |  |  | 20,948,518 |

- 24 -

Table of Contents
12. DISCONTINUED OPERATIONS:
As a result of our financial condition and inability to secure additional funding or significantly improve our liquidity position, management reevaluated its strategic plan. Management developed and implemented a plan to scale back operations. We could not support the working capital needs of four pharmacies, so management decided to close two pharmacies to reduce overall fixed pharmacy costs by 50% and concentrate our limited working capital to support the operations of the two remaining pharmacies that, we believe, have the best prospects. Management considered several factors in determining which two pharmacies to close, including historical financial performance, regulatory costs, current sales prospects, geographic and physical location and strength of existing physician relationships. After consideration of these factors, management closed our Gresham, Oregon and Riverside, California pharmacies on August 5, 2013 and August 8, 2013, respectively.
We recorded approximately $743,317 in expenses related to the closing of the facilities, including lease costs, asset impairment and goodwill impairment during the year ended December 31, 2013. These closures met the discontinued operations criteria and, accordingly, are included in discontinued operations for all periods presented. The Company’s loss from operations of discontinued pharmacies, net of tax benefit for the three and six months ended June 30, 2014 and 2013, respectively are detailed as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013 |
Sales |  | $ | - |  |  | $ | 906,980 |  |  | $ | - |  |  | $ | 2,107,730 |
Cost of sales |  |  | - |  |  |  | 703,682 |  |  |  | - |  |  |  | 1,606,794 |
Gross profit |  |  | - |  |  |  | 203,298 |  |  |  | - |  |  |  | 500,936 |
Operating expenses |  |  | 13,613 |  |  |  | 272,337 |  |  |  | 27,894 |  |  |  | 573,307 |
Impairment of goodwill |  |  | - |  |  |  | 697,766 |  |  |  | - |  |  |  | 697,766 |
Loss from discontinued operations |  |  | (13,613 | ) |  |  | (766,805 | ) |  |  | (27,894 | ) |  |  | (770,137 | )
Other expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | 1,031 |  |  |  | 1,537 |  |  |  | 2,051 |  |  |  | 10,197 |
Tax benefit |  |  | (5,125 | ) |  |  | (268,920 | ) |  |  | (10,481 | ) |  |  | (273,117 | )
Loss from operations of discontinued pharmacies, net of tax benefit |  | $ | (9,519 | ) |  | $ | (499,422 | ) |  | $ | (19,464 | ) |  | $ | (507,217 | )

The Company’s assets and liabilities for discontinued operations included in the consolidated balance sheet as of June 30, 2014 and December 31, 2013 are detailed as follows:

|  | June 30, |  |  | December 31, |
|  | 2014 |  |  | 2013 |
ASSETS |  |  |  |  |  |
Current Assets |  |  |  |  |  |
Accounts receivable, net |  | $ | 468 |  |  | $ | 4,048 |
Prepaid and other current assets |  |  | - |  |  |  | - |
Assets of discontinued operations |  | $ | 468 |  |  | $ | 4,048 |
Other receivables, net |  |  | 136,440 |  |  |  | 140,563 |
Assets of discontinued operations, non-current, net |  | $ | 136,440 |  |  | $ | 140,563 |
LIABILITIES |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  |  | 95,649 |  |  |  | 150,652 |
Liabilities of discontinued operations |  | $ | 95,649 |  |  | $ | 150,652 |

- 25 -

Table of Contents
13. INCOME TAXES
Due to losses incurred for the six months ended June 30, 2014 and 2013, there is no current provision for income taxes.
The utilization of some or all of the Company’s net operating losses may be restricted in the future by a significant change in ownership as defined under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. In addition, utilization of the Company’s California net operating losses for the years prior to 2008 may only be carried forward ten (10) years under State law. The Company’s estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts, and circumstances existing at that time, pursuant to ASC 740. ASC 740 requires a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. At January 1, 2007, (adoption date), and at June 30, 2014, there were no unrecognized tax benefits.
The federal statute of limitations remains open for tax years 2010 through 2013. State jurisdictions generally have statutes of limitations ranging from three to five years. The Company is no longer subject to state income tax examinations by tax authorities for years before 2009.
Any interest and penalties associated with tax positions taken by the Company would be recorded as a component of other expenses in the consolidated statement of operations. For the six months ended June 30, 2014 and 2013, there were no interest or penalties associated with tax positions taken by the Company.
14. SUBSEQUENT EVENTS
In July 2014, the Company issued 100 shares of Series D Preferred Stock to an existing investor for $1,000 per share for an aggregate purchase price of $100,000. For each share of Series D Preferred Stock purchased, two five-year warrants were issued as follows: (i) a Series A Warrant to purchase 2,000 shares of the Company’s common stock; and (ii) a Series B Warrant to purchase 2,000 shares of common stock.
On July 15, 2014, the Company granted stock options to purchase an aggregate of 1,100,000 common shares to key employees under the 2012 Incentive Compensation Plan.
- 26 -

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “should,” “could,” “will,” “plan,” “future,” “continue,” and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on our expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond our control. Therefore, actual results could differ materially from the forward-looking statements contained in this document, and readers are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this document will, in fact, transpire or prove to be accurate.
These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Some of the factors that we believe could affect our results include:

● | limitations on our ability to continue operations and implement our business plan;
● | our history of operating losses;
● | our inability to make timely payments to convertible debenture and secured debt holders;
● | the timing of and our ability to obtain financing on acceptable terms;
● | dependence on one key supplier;
● | the effects of changing economic conditions;
● | the loss of members of the management team or other key personnel;
● | changes in governmental laws and regulations, or the interpretation or enforcement thereof and related compliance costs; and/or
● | costs and other effects of legal and administrative proceedings, settlements, investigations and claims, which may not be covered by insurance.

There are likely other factors that could cause our actual results to differ materially from the results referred to in the forward-looking statements. All forward-looking statements attributable to us in this document apply only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events, except as required by law.
In this report, unless the context indicates otherwise: “Assured Pharmacy,” the “Company,” “we,” “our,” “ours” or “us” refer to Assured Pharmacy, Inc., a Nevada corporation, and its subsidiaries.
- 27 -

Table of Contents
Business Overview
We are engaged in the business of establishing and operating pharmacies that specialize in dispensing highly regulated pain medication for chronic pain management. Because our focus is on dispensing medication, we typically do not keep in inventory non-prescription drugs, or health and beauty related products, such as walking canes, bandages and shampoo. We primarily derive our revenue from the sale of prescription medications. The majority of our business is derived from repeat business from our customers and we have limited “walk-in” prescriptions.
As of June 30, 2014, we had two operating pharmacies and two pharmacies that are under development, each of which are wholly-owned through subsidiaries. In April 2014, we opened our pharmacy operation in the Denver, Colorado metropolitan area. The opening date and locations of our pharmacies are as follows:

Location |  | Opening Date
Kirkland, Washington |  | August 11, 2004
Leawood, Kansas |  | November 28, 2011
Greenwood Village, Colorado |  | April 2, 2014

The table set forth below summarizes the number of prescriptions dispensed and the number of patients serviced by our operating pharmacies during the three and six months ended June 30, 2014 and 2013, respectively.

|  | Three months ended |  |  |  |  |  | Six months ended |  |  |  |
|  | June 30, 2014 |  |  | June 30, 2013 |  |  | June 30, 2014 |  |  | June 30, 2013 |
Total Number of Prescriptions1 |  |  | 15,193 |  |  |  | 13,754 |  |  |  | 27,582 |  |  |  | 27,582 |
Total Number of Patients Serviced2 |  |  | 7,963 |  |  |  | 7,248 |  |  |  | 14,517 |  |  |  | 14,256 |

| 1 | “Total Number of Prescriptions” equals the total number of prescriptions dispensed by our operating pharmacies and delivered to or picked up by the customer.

| 2 | “Total Number of Patients Serviced” equals the total number of patients serviced measured on a monthly basis.

Results of Operations for the Three Months Ended June 30, 2014 and 2013
Summarized immediately below and discussed in more detail in the subsequent sub-sections is an analysis of our operating results for the three months ended June 30, 2014 and 2013, represented as a percentage of total sales for each respective period:

|  | Three Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Sales |  |  | 100.0 | % |  |  | 100.0 | %
Cost of sales |  |  | 81.1 |  |  |  | 76.8 |
Gross profit |  |  | 18.9 |  |  |  | 23.2 |
Operating expenses |  |  |  |  |  |  |  |
Salaries and related expenses |  |  | 22.9 |  |  |  | 37.7 |
Selling, general and administrative |  |  | 21.4 |  |  |  | 57.1 |
Total operating expenses |  |  | 44.3 |  |  |  | 94.8 |
Loss from continuing operations |  |  | (25.4 | ) |  |  | (71.6) |
Other expenses |  |  |  |  |  |  |  |
Interest expense, net |  |  | 7.5 |  |  |  | 21.9 |
Loss on change in forward contract liability |  |  | - |  |  |  | 2.6 |
Gain on change in fair market value of derivative |  |  | (3.0) |  |  |  | - |
Gain on change in fair value of warrant liability |  |  | (5.5) |  |  |  | (17.9) |
Total other expenses and income |  |  | (1.0) |  |  |  | 6.6 |
Net loss from continuing operations, before tax |  |  | (24.4) |  |  |  | (78.1) |
Income taxes |  |  | 0.2 |  |  |  | 19.5 |
Net loss from continuing operations, net of tax |  |  | (24.6) |  |  |  | (97.6) |
Net loss from discontinued operations, net of tax |  |  | (0.4) |  |  |  | (36.2) |
Net loss |  |  | (25.0) |  |  |  | (133.8 | )

- 28 -

Table of Contents
Sales
Our total sales reported for the three months ended June 30, 2014 was $2,177,197, a 57.7% increase from $1,380,955 for the three months ended June 30, 2013. Our sales for the three months ended June 30, 2014 and 2013 was generated primarily from the sale of prescription drugs through our pharmacy operations and to a much lesser extent fees from management services provided.
Sales per prescription dispensed by our pharmacies was approximately $143 per prescription for the three months ended June 30, 2014, a 43.1% increase from approximately $100 per prescription for the three months ended June 30, 2013. The increase in our sales per prescription dispensed is primarily attributable to a shift in prescription mix from lower priced generic medications to higher priced brand medications.
The number of prescriptions dispensed by our pharmacies was 15,193 for the three months ended June 30, 2014, compared to 13,754 for the three months ended June 30, 2013. Management attributes the increase in prescription volumes to the opening our pharmacy in the Denver, Colorado metropolitan area and improved inventory purchasing.
The number of patients serviced by our pharmacies was 7,963 for the three months ended June 30, 2014 compared to 7,248 patients for the three months ended June 30, 2013.
Cost of Sales
The total cost of sales for the three months ended June 30, 2014 was $1,765,861, a 66.5% increase from $1,060,425 for the three months ended June 30, 2013. The cost of sales consists primarily of direct cost of prescription drugs. The increase in cost of sales is primarily attributable to increased sales in the reporting period.
Gross Profit
Our total gross profit increased to $411,336, or approximately 18.9% of sales, for the three months ended June 30, 2014. This is an increase from a gross profit of $320,530, or approximately 23.2% of sales for the three months ended June 30, 2013. The decrease in the gross profit percentage for the three months ended June 30, 2014, when compared to the prior fiscal three months, is primarily attributable to a shift in prescription mix.
Operating Expenses
Operating expense for the three months ended June 30, 2014 was $966,073, a 26.2% decrease from $1,308,956 for the three months ended June 30, 2013. Our operating expenses for the three months ended June 30, 2014 consisted of salaries and related expenses of $499,487 and selling, general and administrative expenses of $466,586. Our operating expenses for the three months ended June 30, 2013 consisted of salaries and related expenses of $520,642 and selling, general and administrative expenses of $788,314.
Salaries and related expenses decreased $21,155 in the three months ended June 30, 2014, when compared to the three months ended June 30, 2013, primarily due to staff reductions.
Selling, general and administrative expenses decreased $321,728 in the three months ended June 30, 2014 when compared to the three months ended June 30, 2013. The significant components of selling, general and administrative expenses are as follows:

|  | Three Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Stock-based compensation expenses |  | $ | 33,313 |  |  | $ | 232,998 |
Provision (recoveries) for accounts receivable doubtful accounts |  |  | 10,609 |  |  |  | 21,286 |
Selling expenses |  |  | 25,636 |  |  |  | 7,843 |
Professional fees |  |  | 71,755 |  |  |  | 271,527 |
Delivery expenses |  |  | 81,362 |  |  |  | 54,173 |
Facility related expenses |  |  | 65,757 |  |  |  | 62,719 |
Travel and related expenses |  |  | 34,364 |  |  |  | 41,158 |
Vendor late fee expenses |  |  | 1,081 |  |  |  | 1,007 |
Investor relations expense |  |  | - |  |  |  | 6,000 |
Other general and administrative expenses |  |  | 142,709 |  |  |  | 89,603 |
Total |  | $ | 466,586 |  |  | $ | 788,314 |

- 29 -

Table of Contents
The decr ease in selling, general and administrative expenses is primarily due to a decrease in stock-based compensation of $199,685 and decreases in professional fees of $199,772 and to a lesser extent a decrease in provision for accounts receivable doubtful accounts, travel expenses and investor relation expenses selling expenses which were partially offset by increases in delivery expenses, selling expenses, other general and administrative expenses and facility related expenses. The increase in delivery expenses are primarily due to an increase in the number of deliveries and pick ups from our customers.
Other (Income) Expense
Total other income for the three months ended June 30, 2014 was $21,128, a $111,882 decrease from $90,754 in other expense for the three months ended June 30, 2013. The significant components of other income and expenses are as follows:

| Three Months ended June 30, |
| 2014 |  | 2013 |
Interest expense, net |  | $ | 163,233 |  |  | $ | 302,631 |
Loss on change in fair value of forward contract |  |  | - |  |  |  | 35,418 |
Gain on change in fair value of derivative |  |  | (64,650 | ) |  |  | - |
Gain on change in fair value of warrants |  |  | (119,711 | ) |  |  | (247,295 | )
Total |  | $ | (21,128 | ) |  | $ | 90,754 |

The decrease was primarily attributable to a $139,398 decrease in interest expense and a $64,650 gain on change in fair value of derivative and to a lesser extent a $35,418 increase in the change in fair value of forward contract liability, which was partially offset by a decrease in the gain in fair value of warrant liability $127,584.
The gain on change in fair value of warrant liability represents the change in fair value calculated on warrants issued in connection with private placements in the fiscal years 2011 through 2013 which grant the warrant holder certain anti-dilution protection and provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
The gain on change in fair value of forward contract liability represents the change in fair value calculated on forward contract issued in connection with our 2013 private placement of common stock. The Company also agreed that the 38,462 shares of common stock included in the units are subject to increase and the $0.65 per share value is subject to decrease, in each case based on the level of the Company’s consolidated net revenues that are derived during our 2013 fiscal year (the “Make-Whole Adjustments”).
The gain on change in fair value of derivative represents the change in fair value calculated on derivative issued in connection with our 2013 Series D Preferred Stock issuances. The derivative relates to the conversion feature into common stock at an initial rate of 2,000 common shares for each share of Series D Preferred Stock, subject to adjustment for certain anti-dilution protection and provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
Our total outstanding debt decreased to $6,342,133 as of June 30, 2014 as compared to $7,292,504 at June 30, 2013. The table below summarizes the components of interest expense for the three months ended June 30, 2014 and 2013:

|  | Three Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Interest expense at stated rates (6.25% - 20.00%) |  | $ | 132,893 |  |  | $ | 107,352 |
Amortization of deferred financing costs |  |  | 2,737 |  |  |  | 19,534 |
Amortization of debt discount |  |  | 27,603 |  |  |  | 175,745 |
Interest expense, net |  | $ | 163,233 |  |  | $ | 302,631 |

The decrease in interest expense is primarily due to a decrease in amortization of debt discount of $148,142 and to a lesser extent an $16,797 decrease in amortization of deferred financing costs, which was partially offset by a $25,541 increase in interest expense at the stated rates due to an decrease in the average debt outstanding for the three months ended June 30, 2014, compared to the three months ended June 30, 2013.
- 30 -

Table of Contents
Loss from Discontinued Operations, net of tax
Discontinued operations include the operations of our Riverside, California and Gresham, Oregon pharmacies closed in August 2013. Our net loss from discontinued operations for the three months ended June 30, 2014 was $9,519, compared to a net loss of $499,422 for the three months ended June 30, 2013.
Net Loss
Our net loss for the three months ended June 30, 2014 was $548,254, compared to a net loss of $1,847,522 for the three months ended June 30, 2013. The decrease in our net loss was primarily attributable to a decrease in operating expenses of $342,883 and a decrease in the loss on discontinued operations, net of tax of $489,904 and to a lesser extent, a decrease in other expenses of $111,882 and an increase in gross profit of $90,806.
Our net loss per common share for the three months ended June 30, 2014 was $0.05, compared to a net loss per common share of $0.32 for the three months ended June 30, 2013. The decrease to our net loss per common share was primarily attributable to a $1,299,269 decrease in our net loss applicable to common stock and an increase in the weighted average number of common shares outstanding to 11,503,294 for the three months ended June 30, 2014, from 5,817,053 for the three months ended June 30, 2013.
Results of Operations for the Six Months Ended June 30, 2014 and 2013
Summarized immediately below and discussed in more detail in the subsequent sub-sections is an analysis of our operating results for the six months ended June 30, 2014 and 2013, represented as a percentage of total sales for each respective period:

|  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Sales |  |  | 100.0 | % |  |  | 100.0 | %
Cost of sales |  |  | 80.3 |  |  |  | 77.4 |
Gross profit |  |  | 19.7 |  |  |  | 22.6 |
Operating expenses |  |  |  |  |  |  |  |
Salaries and related expenses |  |  | 24.7 |  |  |  | 33.7 |
Selling, general and administrative |  |  | 24.0 |  |  |  | 42.9 |
Total operating expenses |  |  | 48.7 |  |  |  | 76.6 |
Loss from continuing operations |  |  | (29.1 | ) |  |  | (54.0) |
Other expenses |  |  |  |  |  |  |  |
Interest expense, net |  |  | 8.5 |  |  |  | 18.9 |
Gain on extinguishment of debt |  |  | (5.6) |  |  |  | - |
Loss on change in forward contract liability |  |  | - |  |  |  | 3.2 |
Gain on change in fair market value of derivative |  |  | (3.3) |  |  |  | - |
Gain on change in fair value of warrant liability |  |  | (11.7) |  |  |  | (4.5) |
Total other expenses and income |  |  | (12.2) |  |  |  | 17.6 |
Net loss from continuing operations, before tax |  |  | (16.9) |  |  |  | (71.6) |
Income taxes |  |  | 0.3 |  |  |  | 8.9 |
Net loss from continuing operations, net of tax |  |  | (17.2) |  |  |  | (80.5) |
Net loss from discontinued operations, net of tax |  |  | (0.5 |  |  |  | (16.5) |
Net loss |  |  | (17.7) |  |  |  | (97.0) |

- 31 -

Table of Contents
Sales
Our total sales reported for the six months ended June 30, 2014 was $3,797,389, a 23.6% increase from $3,073,500 for the six months ended June 30, 2013. Our sales for the six months ended June 30, 2014 and 2013 was generated primarily from the sale of prescription drugs through our pharmacy operations and to a much lesser extent fees from management services provided.
Sales per prescription dispensed by our pharmacies was approximately $138 per prescription for the six months ended June 30, 2014, a 24.3% increase from approximately $111 per prescription for the six months ended June 30, 2013. The increase in our sales per prescription dispensed is primarily attributable to a shift in prescription mix from lower priced generic medications to higher priced brand medications.
The number of prescriptions dispensed by our pharmacies was 27,582 for the six months ended June 30, 2014 compared to 27,582 for the six months ended June 30, 2013. The number of patients serviced by our pharmacies was 14,517 for the six months ended June 30, 2014 compared to 14,256 patients for the six months ended June 30, 2013.
Cost of Sales
The total cost of sales for the six months ended June 30, 2014 was $3,049,675, a 28.2% increase from $2,378,348 for the six months ended June 30, 2013. The cost of sales consists primarily of direct cost of prescription drugs. The increase in cost of sales is primarily attributable to increased sales and prescription mix in the reporting period.
Gross Profit
Our total gross profit increased to $747,714, or approximately 19.7% of sales, for the six months ended June 30, 2014. This is an increase from a gross profit of $695,152 or approximately 22.6% of sales for the six months ended June 30, 2013. The decrease in the gross profit percentage for the six months ended June 30, 2014, when compared to the prior fiscal six months, is primarily attributable to a shift in prescription mix.
Operating Expenses
Operating expense for the six months ended June 30, 2014 was $1,852,972, a 21.3% decrease from $2,354,035 for the six months ended June 30, 2013. Our operating expenses for the six months ended June 30, 2014 consisted of salaries and related expenses of $939,767 and selling, general and administrative expenses of $913,205. Our operating expenses for the six months ended June 30, 2013 consisted of salaries and related expenses of $1,034,331 and selling, general and administrative expenses of $1,319,704.
Salaries and related expenses decreased $94,564 in the six months ended June 30, 2014, when compared to the six months ended June 30, 2013 primarily due to staff reductions.
Selling, general and administrative expenses decreased $406,499 in the six months ended June 30, 2014 when compared to the six months ended June 30, 2013. The significant components of selling, general and administrative expenses are as follows:

|  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Stock-based compensation expenses |  | $ | 99,937 |  |  | $ | 436,777 |
Provision (recoveries) for accounts receivable doubtful accounts |  |  | 18,912 |  |  |  | 9,564 |
Selling expenses |  |  | 36,820 |  |  |  | 22,744 |
Professional fees |  |  | 157,961 |  |  |  | 366,946 |
Delivery expenses |  |  | 155,397 |  |  |  | 105,283 |
Facility related expenses |  |  | 127,730 |  |  |  | 118,067 |
Travel and related expenses |  |  | 76,103 |  |  |  | 72,078 |
Vendor late fee expenses |  |  | 3,756 |  |  |  | 8,459 |
Investor relations expense |  |  | 1,638 |  |  |  | 6,000 |
Other general and administrative expenses |  |  | 234,951 |  |  |  | 173,786 |
Total |  | $ | 913,205 |  |  | $ | 1,319,704 |

- 32 -

Table of Contents
The decrease in selling, general and administrative expenses is primarily due to a decrease in stock-based compensation of $336,840 and a $208,985 decreases in professional fees and to a lesser extent decreases in vendor late fee expenses and investor relation expenses which were partially offset by increases in delivery expenses, selling expenses, provision for accounts receivable doubtful accounts, other general and administrative expenses and facility related expenses. The increase in delivery expenses are primarily due to an increase in the number of deliveries and pick ups from our customers.
Other (Income) Expense
Total other income for the six months ended June 30, 2014 was $461,691, an $1,003,009 decrease from $541,318 in other expense for the six months ended June 30, 2013. The significant components of other income and expenses are as follows:

|  | Six Months ended June 30, |
|  | 2014 |  |  | 2013 |
Interest expense, net |  | $ | 322,449 |  |  | $ | 582,017 |
Gain on extinguishment of debt |  |  | (213,433 | ) |  |  | - |
Loss on change in fair value of forward contract |  |  | - |  |  |  | 97,632 |
Gain on change in fair value of derivative |  |  | (126,691 | ) |  |  | - |
Gain on change in fair value of warrants |  |  | (444,016 | ) |  |  | (138,331 | )
Total |  | $ | (461,691 | ) |  | $ | 541,318 |

The decrease was primarily attributable to a $305,685 decrease in the change in fair value of warrants, a gain on extinguishment of debt of $213,433, a decrease of $259,568 in interest expense, a $126,691gain on change in fair value of derivative and a $97,632 decrease in change in fair value of forward contract.
The $213,433 gain on extinguishment of debt for the six months ended June 30, 2014 resulted from troubled debt restructurings that met the requirements for extinguishment accounting treatment.
The gain on change in fair value of warrant liability represents the change in fair value calculated on warrants issued in connection with private placements in the fiscal years 2011through 2013 which grant the warrant holder certain anti-dilution protection and provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
The gain on change in fair value of forward contract liability represents the change in fair value calculated on forward contract issued in connection with our 2013 private placement of common stock. The Company also agreed that the 38,462 shares of common stock included in the units is subject to increase and the $0.65 per share value is subject to decrease, in each case based on the level of the Company’s consolidated net revenues that are derived during our 2013 fiscal year (the “Make-Whole Adjustments”).
The gain on change in fair value of derivative represents the change in fair value calculated on derivative issued in connection with our 2013 Series D Preferred stock issuances. The derivative relates to the conversion feature into common stock at an initial rate of 2,000 common shares for each share of Series D Preferred stock, subject to adjustment for certain anti-dilution protection and provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
Our total outstanding debt decreased to $6,342,133 as of June 30, 2014 as compared to $7,292,504 at June 30, 2013. The table below summarizes the components of interest expense for the six months ended June 30, 2014 and 2013:

|  | Six Months Ended June 30, |
|  | 2014 |  |  | 2013 |
Interest expense at stated rates (6.25% - 20.00%) |  | $ | 292,109 |  |  | $ | 386,738 |
Amortization of deferred financing costs |  |  | 2,737 |  |  |  | 19,534 |
Amortization of debt discount |  |  | 27,603 |  |  |  | 175,745 |
Interest expense, net |  | $ | 322,449 |  |  | $ | 582,017 |

The decrease in interest expense is primarily due to a decrease in amortization of debt discount of $148,142 and a $94,629 decrease in interest expense at the stated rates due to an decrease in the average debt outstanding for the six months ended June 30, 2014 compared to the six months ended June 30, 2013, and to a lesser extent an $16,797 decrease in amortization of deferred financing costs and
- 33 -

Table of Contents
Loss from Discontinued Operations, net of tax
Discontinued operations include the operations of our Riverside, California and Gresham, Oregon pharmacies closed in August 2013. Our net loss from discontinued operations for the six months ended June 30, 2014 was $19,464, compared to a net loss of $507,217 for the six months ended June 30, 2013.
Net Loss
Our net loss for the six months ended June 30, 2014 was $673,512, compared to a net loss of $2,980,535 for the six months ended June 30, 2013. The decrease in our net loss was primarily attributable to a decrease in other expenses of $1,003,009 and to a lesser extent, a decrease in operating expenses of $501,063, a decrease in the loss on discontinued operations, net of tax of $487,753 and an increase in gross profit of $52,562.
Our net loss per common share for the six months ended June 30, 2014 was $0.12, compared to a net loss per common share of $0.56 for the six months ended June 30, 2013. The decrease to our net loss per common share was primarily attributable to a $1,644,966 increase in our net loss applicable to common stock and an increase in the weighted average number of common shares outstanding to 11,414,481 for the six months ended June 30, 2014, from 5,361,577 for the six months ended June 30, 2013.
Financial condition, Liquidity and Capital Resources
Liquidity and Capital Resources
As of June 30, 2014, we had a cash balance of $24,779, an increase from a balance of $2,856 at December 31, 2013. At June 30, 2014, we had a working capital deficit of $5,873,903, an increase from a working capital deficit of $5,151,054 of December 31, 2013. The increase in our working capital deficit was primarily attributable to an increase in current liabilities attributable to an increase in notes payable and unsecured debentures, which was partially offset by a decrease in accounts receivable due to the sale of accounts receivable.
Over the last several years, our operations have been funded primarily through the sale of both equity and debt securities and cash made available under certain credit facilities. In order for us to finance operations, continue our growth plan and service our existing debt, additional funding is required from external sources. We intend to fund operations through increased sales, lower operating expenses and debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements for the next twelve months. Our management is seeking financing and anticipates that its efforts will result in sufficient funds to finance our operations beyond the next twelve months. However, there can be no assurance that the additional financing necessary to finance our operations for the next twelve months will be available to us on acceptable terms, or at all.
Our current cash on hand is insufficient for us to operate our three operating pharmacies at the current level for the next twelve months. Our business plan calls for ongoing expenses in connection with salary expense and establishing additional pharmacies. These expenditures are anticipated to be approximately $2,800,000 for the next twelve months.
As of June 30, 2014, we had $300,000 in debt securities which were due in the year 2012 and $4,503,994 in debt securities which are either past due or will come due in the next twelve months. We are attempting to extend the maturity date of certain of these debt securities, but can provide no assurance that the holders of such securities will agree to extend the maturity date on these securities on acceptable terms. If our debt holders choose not to convert certain of these securities into equity, we will need to repay such debt, or reach an agreement with the debt holders to extend the terms thereof. If we are forced to repay the debt, this need for funds would have a material adverse impact on our business operations, financial condition and prospects, including our ability to operate as a going concern. If we are forced to repay the debt, our current and forecasted levels of cash flows and available cash on hand will not be sufficient to fund our operations for the year 2014. Accordingly, we will be required to obtain additional financing in order to repay the debt, cover operating losses and fund working capital needs. We cannot provide any assurances of the availability of future financing or the terms on which it might be available. In the absence of such financing, we may be forced to scale back or cease operations, liquidate assets, seek additional capital on less favorable terms and/or pursue other remedial measures.
In June 2014, the Company entered into a $1,200,000 Non-Disclosable Revolving Line of Credit Loan with Third Coast Bank SSB due on June 5, 2015. The loan is not subject to an interest rate, but is subject to service charges based on the amount of funds advanced. The loan is secured by the Company’s accounts receivable and is guaranteed by Pinewood Trading Fund, LP, a related party.
- 34 -

Table of Contents
The table below lists our obligations under outstanding notes payable and unsecured convertible debentures, as of June 30, 2014:

|  | Related Party |  |  | Unrelated |  |  | Total |
Secured Debt (1) |  | $ | - |  |  | $ | 3,804,111 |  |  | $ | 3,804,111 |
Revolving Credit facilities (2) |  |  | 527,000 |  |  |  | 30,000 |  |  |  | 557,000 |
Other Notes and Debt (3)(4) |  |  | 440,000 |  |  |  | 42,068 |  |  |  | 482,068 |
Unsecured Convertible Debentures |  |  | - |  |  |  | 1,498,954 |  |  |  | 1,498,954 |
|  |  | 967,000 |  |  |  | 5,375,133 |  |  |  | 6,342,133 |
Less: current portion |  |  | (240,000 | ) |  |  | (4,263,994 | ) |  |  | (4,503,994 | )
|  | $ | 727,000 |  |  | $ | 1,111,139 |  |  | $ | 1,838,139 |

1) | In February 2013, we received a one year loan of $3,828,527 from our primary wholesaler upon conversion of trade payables of $3,534,793 and cancellation of secured loan with a remaining balance of $293,734. The note bears an interest rate of 6.25% per annum, with interest payable monthly. Monthly payment requirements were $27,000 per month for the first four consecutive months, followed by four consecutive monthly principal reductions of $37,000, followed by three consecutive monthly principal reductions of $42,000, with remaining principal and interest due February 1, 2014. In July 2013, the secured loan was amended and the maturity date was extended to February 1, 2016 with monthly payment requirements of $42,000. As of June 30, 2014, the outstanding principal balance on the note was $3,804,111. Due to our current financial condition, we have not made principal and interest payments in the amount of $359,243, as required by the agreement. In March 2014, we entered into a Forbearance Agreement with H.D. Smith Wholesale Drug Co. in which the lender agreed to forbear from accelerating the outstanding balance of the Note and from instituting collection efforts from the date of the agreement through July 1, 2014, provided certain conditions are met. Due to our financial condition, we did not make the required payment on July 1, 2014. We are currently in negotiations to restructure the terms of the note.

2) | As of June 30, 2014, revolving credit facilities consisted of an outstanding balance of $527,000 on a line of credit we entered into with Brockington Securities, Inc., a company under the control of our Chief Executive Officer.

3) | As of June 30, 2014, other notes and debt consisted of the outstanding principal balance of $42,068 due to TPG, LLC in connection with our acquisition of their ownership interest in API, which operated our discontinued pharmacy in Riverside, California.
4) | As of June 30, 2014, other notes and debt with a related party consisted of the outstanding principal balance of $440,000 due to Pinewood Trading Fund, LP under various notes.

Obligations and Commercial Commitments
Not required for smaller reporting companies.
Outstanding Trade Balance. At June 30, 2014, we had an outstanding balance of $26,456 with our primary wholesaler.
Capital Expenditures. At June 30, 2014, we had no material commitments for capital expenditures.
Cash Flows. As of June 30, 2014, we had $24,779 in cash and total current assets in the amount of $533,984 and had current liabilities in the amount of $6,407,887, resulting in a working capital deficit of $5,873,903.
- 35 -

Table of Contents
The following discussion focuses on information in more detail on the main elements of the $21,923 net increase and $11,977 net decrease in cash during the six months ended June 30, 2014 and 2013, respectively included in the accompanying Consolidated Statements of Cash Flows. The table below sets forth a summary of the significant sources and uses of cash for the six months ended June 30:

|  | 2014 |  |  | 2013 |
Cash used in operating activities |  | $ | (464,885 | ) |  | $ | (836,198 | )
Cash used in investing activities |  |  | (11,736 | ) |  |  | (47,649 | )
Cash provided by financing activities |  |  | 498,544 |  |  |  | 871,870 |
Net increase (decrease) in cash |  | $ | 21,923 |  |  | $ | (11,977 | )

Operating activities used $464,885 in cash for the six months ended June 30, 2014 compared to $836,198 in cash used for the six months ended June 30, 2013. For the six months ended June 30, 2014, our net loss of $673,512 plus non-cash income of $632,165 was the primary reason for our negative operating cash flows which were partially offset by a $840,792 change in operating assets and liabilities. The table below summarizes the components of our cash used in operating activities for the six months ended June 30, 2014 and 2013:

|  |  | 2014 |  |  |  | 2013 |
Net loss from operations including non-controlling interest |  | $ | (673,512 | ) |  | $ | (2,980,535 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization of property and equipment |  |  | 13,915 |  |  |  | 15,620 |
Amortization of debt issuance costs |  |  | 2,737 |  |  |  | 19,534 |
Amortization of discount on debt |  |  | 27,603 |  |  |  | 175,745 |
Stock-based compensation |  |  | 99,937 |  |  |  | 426,778 |
Issuance of common stock in lieu of debenture interest |  |  | - |  |  |  | 45,467 |
Gain on extinguishment of debentures and notes |  |  | (213,433 | ) |  |  | - |
Impairment of goodwill |  |  | - |  |  |  | 697,766 |
Provision for accounts receivable doubtful accounts |  |  | 15,540 |  |  |  | 4,404 |
Recoveries of other receivable doubtful accounts |  |  | (7,757 | ) |  |  | (40,097 | )
Gain on change in fair value of forward contract |  |  | - |  |  |  | 97,632 |
Gain on change in fair value of derivative |  |  | (126,691 | ) |  |  | - |
Gain on change in fair value of warrant liability |  |  | (444,016 | ) |  |  | (138,331) |
|  |  | (632,165 | ) |  |  | 1,304,518 |
Changes in operating assets and liabilities: |  |  | 840,792 |  |  |  | 839,819 |
Net cash used in operating activities |  | $ | (464,885 | ) |  | $ | (836,198 | )

Operating assets and liabilities reduced the overall cash deficit in the six months ended June 30, 2014 primarily due to our increases in our accounts payable and accrued expenses and decreases in our accounts receivable due to our accounts receivable revolving credit facility.
Cash used in investing activities was $11,736 in the six months ended June 30, 2014, compared to $47,649 in the six months ended June 30, 2013. Investing activities in the six months ended June 30, 2014 and 2013 consisted entirely of purchases of property and equipment.
- 36 -

Table of Contents
Cash provided by financing activities during the six months ended June 30, 2014 was $498,544 compared to $871,870 in the six months ended June 30, 2013. Over the last several years our operations have been funded primarily through the sale of debt securities and advances from revolving credit facilities made available to us. During the six months ended June 30, 2014 we received net proceeds from related party notes payable of $440,000 and net proceeds on revolving credit facilities of $80,000, which were partially offset by net principal repayments of $21,456 on notes payable and convertible debentures.
Off Balance Sheet Arrangements
As of June 30, 2014, there were no off balance sheet arrangements.
Going Concern Assumption
The consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. As of June 30, 2014, we had an accumulated deficit of approximately $50.0 million, recurring losses from operations and negative cash flow from operating activities for the six months ended June 30, 2014, of approximately $465,000. We also had negative working capital of approximately $5.9 million and debt with maturities within one year in the amount of approximately $4.5 million as of June 30, 2014.
The Company intends to fund operations through raising additional capital through debt financing and equity issuances, increased sales, increased collection activity on past due other receivable balances and reduced expenses, which may be insufficient to fund its capital expenditures, working capital or other cash requirements for the year ending December 31, 2014. The Company is in negotiations with current debt holders to restructure and extend payment terms of the existing short term debt. The Company is seeking additional funds to finance its immediate and long-term operations. The successful outcome of future financing activities cannot be determined at this time and there is no assurance that if achieved, the Company will have sufficient funds to execute its intended business plan or generate positive operating results. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.
In response to these financial issues, management has taken the following actions:
● We are seeking investment capital.
● We are aggressively targeting new physicians.
● We are aggressively seeking to renegotiate past due existing debentures.
Critical Accounting Policies and Estimates
Our analysis and discussion of our financial condition and results of operations is based upon our Consolidated Financial Statements that have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. GAAP provides the framework from which to make these estimates, assumptions and disclosures. We have chosen accounting policies within GAAP that we believe are appropriate to accurately and fairly report our operating results and financial position in a consistent manner. We regularly assess these policies in light of current and forecasted economic conditions. There have been no changes to our critical accounting policies during the quarter ended June 30, 2014. Our accounting policies are stated in Item 7 of Part II of our Annual Report on Form 10-K for the year ended December 31, 2013 and in Note 2 to the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q. We believe the following accounting policies are critical to understanding our results of operations and the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.
Revenue Recognition
We recognize revenue from prescriptions dispensed on an accrual basis when the product is delivered to or picked up by the customer. Payments are received directly from the customer at the point of sale, or the customers’ insurance provider is billed electronically. For third party medical insurance and other claims, authorization to ensure payment is obtained from the customer’s insurance provider before the medication is dispensed to the customer. Authorization is obtained for these sales electronically and a corresponding authorization number is issued by the customers’ insurance provider.
Inventories
Inventories are located at our pharmacy locations. Inventory consists solely of finished products (primarily prescription drugs) and is valued at the lower of first-in, first-out cost (FIFO) or market. Our inventories are maintained on a periodic basis through the performance of physical inventory counts. Our cost of sales is recorded based upon the actual results of the physical inventory counts, and is estimated when a physical inventory is not performed in a particular month. Historically, no significant adjustments have resulted from reconciliations with the physical inventories.
- 37 -

Table of Contents
Inventories are comprised of brand and generic pharmaceutical drugs. Our pharmacies maintain a wide variety of different drug classes, known as Schedule II, Schedule III, and Schedule IV drugs, which vary in degrees of addictiveness. Schedule II drugs, considered narcotics by the United States Drug Enforcement Administration (“DEA”), are the most addictive; hence, they are highly regulated by the DEA and are required to be segregated and secured in a separate cabinet. Schedule III and Schedule IV drugs are less addictive and are not regulated. Because our business model focuses on servicing pain management doctors and chronic pain patients, we carry in inventory a larger amount of Schedule II drugs than most other pharmacies.
Stock-based Compensation
We issue options and restricted shares of common stock to employees and consultants. Stock option and restricted share awards are granted at the fair market value of our common stock on the date of grant.
The Company records all share-based payments at fair value. The total applicable compensation cost is amortized on a straight-line basis over the requisite service period, which is generally the vesting period.
Inflation and Seasonality
Inflation has not materially affected us during the past fiscal year. We do not believe that our business is seasonal in nature, but historically we have seen increased sales in the fourth quarter which management attributes to patient insurance deductibles that expire on December 31st of each year.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
The Company’s management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), performed an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2014. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Based upon that evaluation, the CEO and CFO concluded that, as a result of the material weaknesses in internal control over financial reporting that are described in Item 9A our Annual Report on Form 10-K for the year ended December 31, 2013, the Company’s disclosure controls and procedures were not effective as of June 30, 2014.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect its internal control over financial reporting.
- 38 -

Table of Contents
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims, lawsuits, and disputes with third parties, actions involving allegations of discrimination or breach of contract actions incidental to the normal operations of the business. Providing pharmacy services entails an inherent risk of medical and professional malpractice liability. We may be named as a defendant in such lawsuits and thus become subject to the attendant risk of substantial damage awards. We believe that we have adequate professional and medical malpractice liability insurance coverage. There can be no assurance, however, that we will not be sued, that any such lawsuit will not exceed our insurance coverage, or that we will be able to maintain such coverage at acceptable costs and on favorable terms.
On March 18, 2011, a lawsuit was filed by Tim Chandler, Jodi Marshall, Christie Garner, the Estate of Thomas Pike, Jr., and Angie Hernandez in the Circuit Court of the State of Oregon for Multnomah County against Payette Clinics, P.C., Scott Pecora, Kelly Bell, Penny Steers and our wholly-owned subsidiaries, Assured Pharmacies Northwest, Inc. and Assured Pharmacy Gresham, Inc. The lawsuit arose from allegations that nurse practitioners at Payette Clinics, P.C. prescribed the five plaintiffs controlled substances in amounts that were excessive under the appropriate medical standard of care. Only one of the plaintiffs, Tim Chandler, brought claims against our subsidiaries. Mr. Chandler’s claims against our subsidiaries were for negligence on the basis of allegations that our subsidiaries knew or had reason to know that the prescriptions fell below the standard of care applicable to the prescription of such controlled substances but nonetheless filled the prescriptions. The plaintiffs, as a whole, submitted a prayer for $7,500,000 in damages. Mr. Chandler only seeks “an amount to be proven at trial” for noneconomic damages and unnecessary expenses. Management believes that the allegations against our subsidiaries are without merit and plans to vigorously defend this claim. We have $2,000,000 in insurance coverage for claims relating to pharmacy negligence. This lawsuit has been stayed as a result of a co-defendant in this lawsuit (Payette Clinics, P.C.) having filed for bankruptcy. The bankruptcy has since been discharged and the automatic stay lifted. The case recently came out of abatement and is set for a two-week trial beginning March 16, 2015. The Company has denied any liability and is vigorously defending against this action.
On August 23, 2013, AQR Opportunistic Premium Offshore Fund, LP and CNH Diversified Opportunities Master Account, LP filed a lawsuit against Assured Pharmacy in the Supreme Court of the State of New York. Plaintiffs submitted a Motion for Summary Judgment in Lieu of Complaint against defendants to recover money allegedly owed by Assured Pharmacy, Inc. under two 16% Convertible Debentures totaling $300,000 and issued in and around 2011 in a private placement. On September 19, 2013, Assured removed the action to the United States District Court for the Southern District of New York. All scheduled briefing regarding Plaintiffs’ Motion for Summary Judgment in Lieu of Complaint was fully submitted to the Court as of October 18, 2013, and the parties are currently awaiting a decision and Order. Assured plans to vigorously defend against Plaintiffs’ claims.
On December 16, 2013 a lawsuit was filed by Ann Raffaele, in the Circuit Court of the State of Oregon for Multnomah County against Assured Pharmacy, Inc. and our wholly-owned subsidiaries, Assured Pharmacies Northwest, Inc. and Assured Pharmacy Gresham, Inc. The lawsuit arises from allegations of medical negligence by Dr. Edward Goering, D.O. and Assured Pharmacy. The plaintiff submitted a prayer for $1,500,000 in damages. Management believes that the allegations against the Company are without merit and plans to vigorously defend against this claim. We have $2,000,000 in insurance coverage for claims relating to pharmacy negligence.
On February 19, 2014, a lawsuit was filed by JS Barkats PLLC, in the Supreme Court of The State of New York, County of New York against Assured Pharmacy, Inc. and Robert DelVecchio, our Chief Executive Officer. The lawsuit arises from allegations of failing to remit legal fees due under written retainer agreements of $134,300 and failing to deliver 500,000 freely traded shares of the Company’s common stock pursuant to one of the retainer agreements. Defendants filed a Verified Answer on March 21, 2014. On June 19, 2014, the parties entered into a Preliminary Conference Order setting the timing and sequence of discovery in the action. A Compliance Conference has been scheduled for September 4, 2014. Management believes that the allegations against the Company are without merit and plans to vigorously defend against this claim.
Item 1A. Risk Factors.
The most significant risk factors applicable to the Company are described in Part I Item 1A entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “2013 Form 10-K”). There have been no material changes to the risk factors previously disclosed in the 2013 Form 10-K. Additional risks and uncertainties not known to management may materially adversely affect the Company’s business, financial condition, and/or operating results.
- 39 -

Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following is a summary of recent sales of our securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”).
For each of the following common stock and warrant issuances, these securities were issued upon the exemption from the registration provisions of the Securities Act provided for by Section 4(a)2 and 3(a)(9). There were no underwriters or placement agents employed in connection with any of these transactions.
On January 3, 2014, we issued an aggregate total of 2,019,123 shares of restricted common stock to eight debenture holders upon conversion of $965,784 in debentures and payment of $245,689 in accrued interest on outstanding convertible debentures at the conclusion of our 2013 tender offer.
On February 13, 2014, we issued 420,694 common shares as payment of $252,417 in accrued interest on outstanding convertible debentures to a convertible debenture holder. The aggregate fair market value of the shares on the date of issuance was determined to be $63,104 or $0.15 per share.
On March 14, 2014, we issued 1,175,408 shares of restricted common stock to a debenture holder upon conversion of $500,000 in debentures and payment of $205,245 in accrued interest on outstanding convertible debentures. As part of the transaction, we also issued 833,334 three year warrants to purchase common stock at an initial exercise price of $0.60 for twelve months, with an increase to $0.75 for the remaining 24 months.
On May 2, 2014, we issued an aggregate total of 856 shares of restricted Series D Preferred Stock to three holders pursuant to the milestone provision in the relevant stock purchase agreement. As part of the transaction, we also issued 3,424,000 five-year warrants to purchase common stock at an initial exercise price of $0.40.
On May 30, 2014, we issued an aggregate total of 826,907 shares of restricted common stock to eight common stock holders in accordance with the make-whole provision in our 2013 private placement.
Item 3. Defaults upon Senior Securities.
Due to our current financial condition, we did not make interest and principal payments due under various notes and debentures.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
An Exhibit Index has been attached as part of this Quarterly Report and is incorporated herein by reference.

(a) | Exhibits

31.1 |  | Sarbanes-Oxley Act Section 302 Certification of Robert J. DelVecchio
31.2 |  | Sarbanes-Oxley Act Section 302 Certification of Brett P. Cormier
32.2 |  | Sarbanes-Oxley Act Section 906 Certification of Robert J. DelVecchio and Brett P. Cormier

- 40 -

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 14, 2014.

Assured Pharmacy, Inc.
By: | /s/ Robert DelVecchio
Name: | Robert DelVecchio
Title: | Chief Executive Officer and Director

By: | /s/ Brett Cormier
Name: | Brett Cormier
Title: | Chief Financial Officer and Principal Accounting Officer

- 41 -

Table of Contents
ASSURED PHARMACY, INC.
EXHIBIT INDEX

Exhibit No. |  | Title
31.1 |  | Sarbanes-Oxley Act Section 302 Certification of Robert J. DelVecchio **
31.2 |  | Sarbanes-Oxley Act Section 302 Certification of Brett P. Cormier **
32.2 |  | Sarbanes-Oxley Act Section 906 Certification of Robert J. DelVecchio and Brett P. Cormier **
101.INS † |  | XBRL Instance Document
101.SCH † |  | XBRL Taxonomy Extension Schema Document
101.CAL † |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF † |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB † |  | XBRL Extension Labels Linkbase Document
101.PRE † |  | XBRL Taxonomy Extension Presentation Linkbase Document

** Filed herewith

† In accordance with SEC rules, this interactive data file is deemed “furnished” and not “filed” or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 and Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under those sections or acts.

- 42 -